Postconditioning protects endothelial cells from apoptosis during reperfusion injury : Role of inhibitor of apoptosis protein 2 by Gadiraju, Krishnaveni
 1 
Postconditioning protects endothelial cells from 
apoptosis during reperfusion injury- 
 Role of inhibitor of apoptosis protein 2 
 
 
 
 
 
 
Inaugural Dissertation 
submitted to the 
 Faculty of Medicine 
in partial fulfillment of the requirements 
for the PhD-Degree 
of the Faculties of Veterinary Medicine and Medicine 
of the Justus Liebig University Giessen 
 
 
 
 
by 
Krishnaveni Gadiraju 
of 
Hyderabad, India 
 
 
 
Giessen (2010) 
 2 
From the Institute of Physiology 
Director/Chairman: Prof. Dr. K. D. Schlüter 
of the Faculty of Medicine of the Justus Liebig University Giessen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
First Supervisor and Committee Member: Priv. Doz. Dr. Thomas Noll 
Second Supervisor and Committee Member: Prof. Dr. Henning Morawietz 
Committee Members: Prof. Dr. Ulrich Müller, Prof. Dr. Dr. Stefan Arnhold 
 
 
 
 
 
 
 
Date of Doctoral Defense: 08.09.2010 
 3 
Table of contents 
 
Abbreviations          00  
1. Introduction          09 
1.1 Endothelial apoptosis         09 
1.2 Reperfusion injury         10 
1.3 Apoptosis in reperfusion injury       11 
1.4 The intrinsic pathway         14 
1.5 The extrinsic pathway         15 
1.6 Inhibitors of apoptosis proteins       17 
1.6.1 Structure and function of mammalian IAPs     18 
1.6.2 Mechanism of caspase inhibition by IAPs     20 
1.6.3 Regulation of IAPs         21 
1.7 Postconditioning         23 
1.7.1 Triggers and mediators of postconditioning     25 
1.7.2 Signaling pathways in postconditioning      26 
1.8 Aims and objectives of the project       27 
2. Materials            29 
2.1 Chemicals and reagents        29 
2.2 Pharmacalogical inhibitors        30 
2.3 Antibodies          31 
2.4 siRNA transfection         31 
2.5 Flow cytometry          32 
2.6 Laboratory instruments        32 
2.7 Software           33 
3. Methods           34 
3.1 Preparation of human umbilical vein endothelial cells    34 
3.2 Subcultivation of endothelial cells       35 
3.3 Experimental protocol for hypoxia/reoxygenation and postconditioning 35 
3.4 siRNA transfection of endothelial cells      36 
3.5 Application of pharmacological inhibitors      37 
3.6 FACS analysis          37 
3.7 Protein analysis          37 
3.7.1 Preparation of samples        37 
 4 
3.7.2 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)    38 
3.7.3 Western blotting          39 
3.7.4 Staining of transferred proteins       40  
3.7.5 Immunodetection of proteins       40 
3.7.6 Stripping and reprobing        41 
3.8 Co-immunoprecipitation        42 
3.9 Immunofluorescence         43 
3.10 Intact vessel model         45 
3.11 Statistical analysis         45 
4. Results           46 
4.1 Effect of postconditioning on hypoxia/reoxygenation-induced 
apoptosis in endothelial cells      46 
4.2 Effect of postconditioning on hypoxia/reoxygenation-induced  
cleavage of caspase-3         47 
4.3 Effect of postconditioning on Inhibitor of apoptosis proteins,  
cIAP1, cIAP2 and XIAP         49 
4.4 Effect of cIAP2 silencing on hypoxia/reoxygenation-induced 
apoptosis and postconditioning        51 
4.5 Effect of cIAP2 silencing on hypoxia/reoxygenation-induced 
caspase-3 cleavage and postconditioning      53 
4.6 Effect of hypoxia/reoxygenation and postconditioning on  
cIAP2-procaspase-3 interaction        54 
4.7  Effect of postconditioning on PI3 kinase and MAPKs in 
endothelial  cells          56 
4.8 Role of PI3 kinase and MAPKs in the maintenance of 
cIAP2 by postconditioning         58  
4.9 Effect of hypoxia/reoxygenation and postconditioning on 
cIAP2 expression in the rat aorta        60 
5. Discussion          62 
5.1 Postconditioning protects endothelial cells from 
hypoxia/reoxygenation-induced apoptosis      62 
5.2 Inhibitors of apoptosis proteins in postconditioning    63 
5.3 Effect of cIAP2 silencing on hypoxia/reoxygenation-induced 
apoptosis and postconditioning        64 
 5 
5.4 Interaction of cIAP2 and procaspase-3      65 
5.5 Role of PI3 kinase and MAPKs in the maintenance of 
cIAP2 by postconditioning         66  
5.6 cIAP2 expression in the intact vessel      67 
5.7 Future perspective         67 
6. References          69 
7. Summary           85 
8. Zusammenfassung         86 
9. Declaration          87 
10. Acknowledgments         88 
11. Curriculum vitae         89 
12. Publications          90  
 6 
Abbreviations 
 
Apaf-1  Apoptosis protease activating factor-1 
Apo-1   Apoptosis-inducing protein-1 
APS   Ammonium per sulfate 
Asp   Aspartic acid 
ATP   Adenosine-5-triphosphate 
Bak   Bcl-2 homologue antagonist/killer 
Bax   Bcl-2-associated X protein 
Bcl-2   B-cell lymphoma-2 
bFGF   Basic fibroblast growth factor 
BH3   Bcl-2 homology domain 
BID   Bcl-2 interacting domain 
BIR   Baculoviral IAP repeat 
BSA    Bovine serum albumin 
CaCl2   Calcium chloride 
CARD   Caspase recruitment domain 
cIAPs   Cellular inhibitor of apoptosis proteins 
CPC   Chromosomal passenger complex 
Cyt C   Cytochrome C 
CWFSG  Cold-water fish skin gelatin 
DED   Death effector domain 
DISC   Death-inducing signaling complex 
DMSO  Dimethyl sulfoxide 
DNA   Deoxyribonucleic acid 
DR3-6  Death receptors 3-6 
DTT                         Dithiothreitol 
dUTP                       Deoxy uridine triphosphate   
EC    Endothelial cells 
ECGS   Endothelial cell growth supplement 
ECL    Enhanced chemiluminescence 
ECO   Escherichia Coli Oxyrase 
EDTA   Ethylene diamine tetraacetic acid 
EGTA   Ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid 
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Smac/DIABLO Second mitochondria-derived activator of caspase 
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1. Introduction 
 
1.1 Endothelial apoptosis 
              The endothelium is a monolayer of cells forming the innermost lining of the 
entire circulatory system. It acts as a selectively-permeable membrane barrier 
between the blood and the interstitial spaces. Although historically viewed as a 
passive monolayer merely reducing the turbulence of blood flow, the endothelium 
infact, is a dynamic membrane making many active contributions to cardiovascular 
function. The major contributions of the endothelium include selective blood tissue 
exchange, regulation of vascular tone by vasoactive secretions like nitric oxide (NO), 
endothelium derived hyperpolarizing factor, prostacyclin and endothelin, flow induced 
vasodilatation and constriction and hence control of blood pressure, blood clotting, 
modification of circulating plasma components by angiotensin-converting enzyme, 
inflammatory defence against pathogens and initiation of angiogenesis.  
       The function and integrity of the endothelium, therefore, are absolute necessities 
for the function of the cardiovascular system. However, this integrity is at stake in 
several pathological conditions like ischemia-reperfusion, leading to damage or loss 
of endothelial cells. Under these conditions, apoptosis is the predominant form of cell 
death in the endothelium due to the robust energy metabolism of these cells. The 
ability of endothelial cells to maintain high levels of ATP, even in the adverse 
conditions of hypoxia or ischemia, prevents them from the necrotic fate (Lelli et al., 
1998) (Fig 1.1). Increasing evidence suggests that apoptosis of endothelial cells can 
be responsible for acute and chronic coronary diseases, e.g. through atherogenesis 
(Chen et al., 2004), thrombosis (Bombeli et al., 1997) and endothelial dysfunction 
(Werner et al., 2006), hence jeopardizing the survival of the whole myocardial tissue. 
It is now known that endothelial apoptosis is a critical part of reperfusion injury and it 
is the endothelial cells rather than the cardiomyocytes that begin to undergo 
apoptosis early during reperfusion (Scarabelli et al., 2001). 
       Inspite of the high clinical relevance associated, little is known about the 
mechanisms preventing apoptosis in endothelial cells. The present study focuses on 
hypoxia-reoxygenation induced endothelial apoptosis and its response to 
postconditioning. 
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Fig 1.1 Endothelial apoptosis: a) Apoptosis – necrosis switch by ATP. b) Cross 
section of a rat heart subjected to 35 min ischemia followed by 60 min reperfusion, 
showing TUNEL positive (yellow) apoptotic endothelial cells around the vessel and 
TUNEL positive cardiomyocytes whose number decreases with increasing distance 
from the lumen (Scarabelli et al., 2001). 
 
1.2 Reperfusion injury 
              ‗Ischemia‘, literally meaning restriction of blood flow, is one of the most 
frequent cardiovascular complications and the leading cause of death worldwide. 
Reperfusion or restoration of blood flow remains the definitive strategy for saving the 
myocardium. However, reperfusion has been referred as a ‗double edged sword‘ 
(Braunwald and Kloner, 1985), because reperfusion itself is associated with a series 
of detrimental events that extend the damage beyond that observed during the 
ischemic period alone. These events are collectively called as reperfusion injury. 
Reperfusion injury is not a mere worsening of the ischemia-induced damage, but it 
constitutes processes that are specifically induced by reperfusion per se. It includes 
complex mechanisms involving mechanical, extracellular and intracellular processes. 
Some of the events that trigger reperfusion injury are: 
 Rapid generation of reactive oxygen species (ROS) by activated vascular 
endothelial cells, neutrophils and stressed cardiomyocytes (Ambrosio et al., 
1991). 
 Activation of sodium hydrogen exchanger (Allen et al., 2003) and 
augmentation of ischemia induced cellular and mitochondrial Ca
2+
 overload 
(Piper et al., 1989). 
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 Increased osmotic gradient and cell swelling induced by the accumulation of 
products of anaerobic metabolism (Jennings et al., 1986). 
 Opening of the mitochondrial permeability transition pore (mPTP), resulting in 
influx of otherwise impermeable proteins, mitochondrial swelling, uncoupling of 
oxidative phosphorylation and release of pro-apoptotic molecules like 
cytochrome C (Cyt C) and second mitochondria-derived activator of caspase 
(Smac/DIABLO) into the cytosol (Griffiths et al.,1995). 
 Reduced NO availability (Lefer et al., 1993) leading to the augmented 
expression of cellular adhesion molecules, induction of local inflammation, 
leukocyte infiltration and no-reflow phenomenon. 
The clinical consequences of these events, occurring within minutes of the onset of 
reperfusion are manifested by myocardial stunning or hypercontracture, infarction, 
reperfusion arrhythmias, endothelial dysfunction and cell death by necrosis and 
apoptosis. 
 
1.3 Apoptosis in reperfusion injury          
       Ischemia/reperfusion induces cell death via apoptosis, oncosis and necrosis. 
However, endothelial cells due to their robust energy metabolism undergo apoptosis, 
rather than necrosis.  
          Apoptosis is a controlled process of programmed cell death. The morphology 
of this death process was originally recognized by nineteenth century microscopists. 
Thus, what we now call apoptosis was first described in the epithelial cells of atretic 
ovarian follicles by Flemming in 1885 (Eefting et al., 2004; Scarabelli et al., 2006). 
Morphologically, apoptosis is characterized by cell shrinkage, chromatin 
condensation and migration, DNA fragmentation and blebbing of the plasma 
membrane. Nuclear and cytoplasmic material is surrounded by intact plasma 
membrane and these apoptotic bodies are engulfed by phagocytes. Due to this rapid 
vesiculation and phagocytosis, there is no spilling of intracellular material into the 
surrounding tissue. Therefore, there is less inflammation in the surrounding tissue 
compared to necrosis, where cell swelling and rupture of the plasma membrane lead 
to leakage of cellular content, consequently resulting in a strong inflammatory 
response. Due to its programmed nature, apoptosis is also more amenable to 
therapeutic interventions. Though seemingly opposing insults, both prolonged 
hypoxia/ischemia and reperfusion result in apoptosis, with the burst of reactive 
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oxygen species caused by reperfusion, enhancing the rate of apoptosis initiated by 
hypoxia or ischemia. 
 
DNA fragmentation in ischemia and reperfusion: 
       DNA fragmentation is one of the defining characteristics of apoptosis. It is 
commonly identified by DNA laddering in gel electophoresis and by terminal 
deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) assay. 
Gottlieb et al., (1994) have identified the absence of TUNEL-positive apoptotic cells 
or DNA laddering in the rabbit heart exposed to ischemia alone but did detect DNA 
fragmentation by both these assays during reperfusion following ischemia. In 
contrast, Kajstura et al., (1996) have observed DNA fragmentation by both these 
assays in rat hearts exposed to prolonged ischemia without reperfusion. In a more 
recent study (Zhao et al., 2002), very few TUNEL-positive cells and no DNA 
laddering were detected in the dog heart exposed to ischemia alone, but a very large 
number of TUNEL-positive cells and extensive DNA laddering were observed in the 
peri-necrotic area, after 6 hours of reperfusion. These studies suggest that although 
there may be differences between species and different experimental systems, it is 
likely that the vast majority of DNA fragmentation is confined to the post-ischemic 
period rather than to ischemia itself. This conclusion is reinforced by the work of 
Scarabelli et al., (2001) who observed no TUNEL positivity in both cardiomyocytes 
and endothelial cells of the rat heart exposed to ischemia alone. However, TUNEL 
positivity was detected in endothelial cells after as little as 5 minutes of reperfusion, 
peaked at 60 minutes of reperfusion and decreased at 2 hours of reperfusion. In 
contrast, the proportion of TUNEL-positive cardiac myocytes slowly increased over 2 
hours of reperfusion. As expected, DNA laddering was detected in samples prepared 
after reperfusion but not in samples exposed to ischemia alone. These studies, 
therefore, indicate that apoptosis does occur in the heart, particularly during 
reperfusion, and has a different time-course in endothelial cells compared to cardiac 
myocytes. 
       The importance of apoptosis as a key step in reperfusion injury is supported by 
studies in which such DNA fragmentation was inhibited by treatment with 
aurintricarboxylic acid (ATA), an inhibitor of DNA endonucleases. In these 
experiments, addition of ATA at the onset of reperfusion resulted in reduced infarct 
size and enhanced regional contractile function (Zhao et al., 2003). 
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Translocation of phosphotidylserine in reperfusion injury: 
       Translocation of phosphotidylserine residues from the inner to the outer side of 
the plasma membrane occurs as an outcome of apoptosis. Hence apoptotic cells 
exhibit staining with Annexin V, which binds to phosphotidylserine. 
It has been shown that surface staining with Annexin V appeared in the intact mouse 
heart only during reperfusion and not during the ischemic episode (Dumont et al., 
2000). This reinforces the DNA fragmentation studies that apoptosis occurs 
predominantly during reperfusion. Increased uptake of labeled Annexin V in the 
infarct area was shown in patients with acute myocardial infarction when treated with 
primary coronary angioplasty, confirming the role of apoptosis in reperfusion injury 
(Hofstra et al., 2000).  
 
Caspase activation in reperfusion injury: 
          Caspases are cysteine (Cys)-dependent aspartic acid (Asp)-specific proteases 
that are the key executers of apoptosis. They are constitutively expressed as inactive 
precursor zymogens that are activated in response to an apoptotic stimulus by 
proteolytic cleavage and dimerization, to generate active caspases. Upon activation, 
they execute the cell death process through cleavage of specific structural and 
regulatory proteins necessary for cell survival. Fourteen caspases have been 
identified so far and they are divided into two groups, namely, the initiator and the 
effector caspases.  
           The initiator caspases like -2, -8, -9, -10 and -12 are characterized by the 
presence of long N-terminal regions that contain one or more adaptor domains (death 
effector domain, DED or caspase recruitment domain, CARD), which are absent in 
the effector enzymes. Activation of initiator caspases takes place in a multiprotein 
complex, such as the apoptosome for caspase-9 and the death-inducing signaling 
complex (DISC) for caspase-8. Active initiator caspases consequently activate 
downstream effector caspases, such as caspase-3, -6, and -7 by cleavage at internal 
Asp residues. Effector caspases are expressed as homodimers and their activation 
involves intrachain cleavage that generates fragments of ~10 and ~20 kDa still in a 
dimeric form. Active effector caspases recognize a 4-amino-acid motif in their 
substrates, P4-P3-P2-P1, and cleave after the C-terminal (P1) Asp. Over 280 such 
caspase substrates have been identified and most of them are structural or 
regulatory proteins whose function is inactivated by caspase cleavage (Fischer et al., 
 14 
2003). In some cases the cleaved fragment also helps to augment the apoptotic 
process (Scarabelli et al., 2006). 
The initiator caspases -8, -9 and -12 and the effector caspases -3, -6 and -7 have 
been shown to be involved in ischemia-reperfusion induced apoptosis. Activation of 
these caspases in response to ischemia-reperfusion involves both the intrinsic and 
the extrinsic pathways (Scarabelli et al., 2006).  
 
1.4 The intrinsic pathway 
        The intrinsic pathway is also called the mitochondrial pathway and is employed 
by a wide range of apoptotic stimuli that converge on the mitochondria. These stimuli 
affect the mitochondria in different ways by either altering the permeability or by 
membrane swelling and disruption. Caspase-9 is the principle initiator caspase of the 
intrinsic pathway. Release of Cyt C from the inner mitochondrial membrane into the 
cytosol is the critical initiating step of mitochondria-mediated apoptosis. In the 
cytosol, Cyt C binds to apoptosis protease activating factor (Apaf-1), in the presence 
of ATP. Procaspase-9 is recruited to, and activated, in this complex, called the 
apoptosome (Adrain et al., 2001). Active caspase-9 subsequently cleaves the 
effector caspases -3, -6 and -7 thereby activating them.  
          Cyt C release has been observed in the intact heart exposed to 
ischemia/reperfusion, with its translocation from mitochondria to the cytosol 
becoming maximal during the reperfusion phase (Narula et al., 1999) and was 
associated with caspase-9 activation (Scheubel et al., 2002). The key role for Cyt C 
is further supported by studies in which inhibition of Cyt C release was found to block 
apoptosis (Borutaite et al., 2003), whereas its addition to heart cytosol was shown to 
be sufficient to induce apoptosis (Borutaite et al., 2001). Release of Cyt C is 
governed by the integration of the Bcl-2 family proteins, Bax and Bak that form 
channels in the mitochondrial membrane or by the opening of the mPTP.  
          mPTP is a protein pore spanning across the inner and outer mitochondrial 
membranes together with proteins of the intermembrane space. Its opening, apart 
from Cyt C release, results in release of other pro-apoptotic molecules like Smac/ 
DIABLO, production of ROS, release of mitochondrial NADH and influx of ions such 
as calcium, causing swelling of the mitochondria.  Inhibition of the mPTP in rat hearts 
by cyclosporine A (Griffiths et al., 1995) and sanglifehrin A (Hausenloy et al., 2003) 
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during reoxygenation was observed to be protective against ischemia-reperfusion 
injury. 
 
1.5 The extrinsic pathway 
       The extrinsic pathway or the death receptor pathway operates via ubiquitously 
expressed cell surface receptors characterized by the presence of a death domain. 
Six death receptors have been identified, including CD95 (also known as APO-1, 
Fas), TNFα receptor-1 (TNFR1), and death receptors 3-6 (DR 3-6), and all of these 
are expressed in the heart (Spierings et al., 2004). Their corresponding ligands, 
CD95 ligand (CD95L), tumor necrosis factor-α (TNFα), and TNFα-related apoptosis-
inducing ligand (TRAIL), are also expressed in the heart. On ligation to the receptors, 
the death domains transduce the apoptotic signal by recruiting adaptor molecules 
(e.g. Fas-associated death domain (FADD) or TNF receptor-associated death 
domain (TRADD)), which in turn, recruit the enzymatically inactive procaspase-8. The 
resulting complex is known as the death inducing signaling complex (DISC). The 
recruitment of procaspase-8 to the DISC results in its oligomerization and activation 
through selfcleavage. The enzymatically active caspase-8 then cleaves downstream 
caspases, such as caspases-3, -6, and -7.  
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Fig 1.2 Cross talk between the intrinsic and extrinsic apoptotic pathways converging 
at effector caspases and their inhibitors, the IAPs. 
         
 
Though the molecular cascades employed are distinct to each pathway, the 
mitochondrial and the death receptor mediated apoptotic pathways are not mutually 
exclusive. Procaspase-8 activated by stimulation of the death receptors, can activate 
the BH3 only protein, BID, whose cleavage product, tBID, migrates into the 
mitochondria, disrupting the membrane. This disruption causes the translocation of 
Cyt C to the cytoplasm interlinking both the apoptotic pathways (Luo et al., 1998).  
        Evidence is now available that both caspase-8, the initiator caspase of the 
extrinsic pathway and caspase-9, the initiator caspase of the intrinsic pathway, play 
important but distinct roles in reperfusion injury. Specific inhibitors of either caspase-9 
or caspase-8 given at reperfusion were able to reduce infarct size in the isolated rat 
heart (Scarabelli et al., 2002). More detailed studies in cultured cardiac cells 
(Stephanou et al., 2001) have indicated that both chemical and gene-based inhibitors 
of caspase-9 can reduce apoptotic cell death in cardiomyocytes exposed to 
 17 
simulated ischemia alone, whereas inhibition of caspase-8 has no effect. In contrast, 
inhibition of either caspase-8 or caspase-9 was able to reduce apoptotic cell death in 
response to ischemia/reperfusion. These studies in cultured cardiac cells were 
supported by further studies in the intact isolated heart exposed to 
ischemia/reperfusion that demonstrated activation of caspase-9 during ischemia 
alone with further activation during reperfusion, whereas caspase-8 was only 
activated by reperfusion following ischemia (Scarabelli et al., 2002). In addition to this 
difference in the activation of the two caspases during ischemia and reperfusion, 
another interesting observation was that their activation differs in endothelial cells 
and cardiomyocytes. Activation of caspase-9 was observed primarily in endothelial 
cells and only to a much lesser extent in cardiac myocytes, whereas activation of 
caspase-8 was only observed in cardiac myocytes. In agreement with this, a specific 
caspase-9 inhibitor prevented endothelial apoptosis in this system, whereas a 
specific caspase-8 inhibitor affected only cardiac myocyte apoptosis (Scarabelli et al., 
2002). In this study, it was also shown that endothelial apoptosis preceeds 
cardiomyocyte apoptosis, in the heart exposed to ischemia/reperfusion.  
        Taken together, these findings on the time-course of apoptosis in the different 
cell types suggest a model in which activation of caspase-9 during ischemia itself 
leads to initiation of apoptosis, primarily in the endothelium, which futher extends to 
cardiomyocytes and continues during reperfusion as well. On the other hand, 
caspase-8, which is the principal initiator caspase in cardiomyocytes, is activated 
only at reperfusion and not during ischemia. This clearly indicates that endothelial 
apoptosis is one of the initiating events of reperfusion injury and is central to the 
outcome of myocardial damage.  
 
1.6 Inhibitors of apoptosis proteins 
       As their name implies, the IAPs (inhibitor of apoptosis proteins), are a family of 
proteins that confer protection to the cell by counteracting apoptotic execution. They 
are characterized by the presence of at least one baculovirus IAP repeat (BIR) 
domain, reflecting their original discovery in baculovirus. A genetic screen to identify 
regulators of host cell viability led to this discovery of IAPs (Crook et al., 1993), which 
was followed by identification of cellular orthologues in species as diverse as yeast 
(Uren et al., 1999), nematodes (Fraser et al., 1999), flies (Hay et al., 1995) and 
humans (Duckett et al., 1996; Liston et al., 1996). Eight human IAPs have been 
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identified so far and their regulation has been implicated in the maintenance of tissue 
homeostasis in several physiological and pathophysiological situations like acute 
myelogenous leukaemia (Tamm et al., 2000), MALT lymphoma (Dierlamm et al., 
1999), melanomas (Vucic et al., 2000), oesophageal squamous-cell carcinoma 
(Imoto et al., 2001), neuro-degenerative disorders (Roy et al., 1995) and in ischemia 
(Dong et al., 2001).  
 
1.6.1 Structure and function of mammalian IAPs  
         Three major domains, namely, the BIR domain, the RING finger and the CARD 
domain constitute mammalian IAPs, though not all of them are present in all the eight 
proteins of the family (Fig 1.3).  
    
BIR Domain: The BIR domain is a ~ 70 to 80 amino acid zinc-binding domain, the 
existence of which in a protein constitutes membership of the IAP family (Miller et al., 
1999; Hinds et al., 1999; Sun et al., 1999). It comprises three short β-strands and 
four α-helices that fold into a compact structure containing a zinc ion coordinated by 
conserved histidine and cysteine residues (Hinds et al., 1999). The BIR domain 
sequences are strongly conserved from viral to mammalian IAPs and have a 
remarkable structural similarity. However, specific sequence differences underlie the 
distinct binding properties of each of the BIR domain. One to three copies of this 
motif have been identified in numerous proteins, not all of which have clear links with 
apoptosis. Indeed, IAPs are sometimes referred by the alternative nomenclature of 
BIRPS (BIR-containing proteins), as some BIR-containing proteins do not seem to 
function as bona fide inhibitors of apoptosis, but all IAPs are BIR-containing proteins 
(Uren et al., 1998). The BIRs are essential for the anti-apoptotic properties of the 
IAPs (Duckett et al., 1996) and in several cases this has been directly attributed to 
the binding and inhibition of caspases (Devereaux et al., 1997).  
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Fig 1.3 Domain repersentation of the mammalian IAPs: Each member of the family 
has atleast one BIR or baculoviral IAP repeat. CARD or caspase recruitment domain 
is found only in cellular IAP1 (cIAP1) and cellular IAP2 (cIAP2). RING finger is 
present at the carboxy terminal in all except neuronal IAP (NIAP), Survivin and 
Appolon. 
 
 
RING Domain: The prototype baculoviral IAPs, and several cellular IAPs, contain a 
second type of zinc-binding motif known as the RING (really interesting new gene) 
domain (Joazeiro et al., 2000). In an IAP that contains a RING domain, this motif is 
invariantly found at the extreme carboxyl terminus of the protein. It is a small ~ 40 
amino acid domain that is defined by eight cysteine and histidine residues that 
coordinate two zinc ions. Although RING domains have been identified in various 
proteins with different functions, the RINGs of IAPs are much more closely related to 
each other than they are to the RINGs of other proteins. This indicates that they 
might have evolved, and retained, a specialized function. The RING domain 
possesses dimerization and E3 ligase activity (Silke et al., 2005) that enables RING-
containing proteins to catalyse the degradation of both themselves and selected 
target proteins through ubiquitination. 
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CARD Domain: The caspase recruitment domain (CARD) is another conserved 
domain that is found only in cIAP1 and cIAP2. The structure and function of CARD in 
these molecules has not been determined. However, given the conserved nature of 
this domain, it is highly likely that in IAPs the CARD forms a six-helix bundle, which 
serves as a protein-protein interaction motif (Park et al., 2007).  
 
Non-apoptotic functions: Keeping up to their name as inhibitors of apoptosis, IAPs 
are the key regulators of programmed cell death occurring in various physiological 
and pathophysiological processes including cancers, neurological disorders and 
ischemia-reperfusion diseases. However, the function of IAPs is not restricted to anti-
apoptosis. There is a rapidly growing body of evidence that an important, if not a 
predominant, role of IAPs is the regulation of a diverse set of non-apoptotic signaling 
pathways, including those involved in cell cycle regulation, morphogenesis, MAP 
Kinase activation, NF-kB activation, innate immunity and even in heavy metal 
metabolism (Srivasula et al., 2008). 
 
1.6.2 Mechanism of caspase inhibition by IAPs 
        The BIR domains of IAPs allow them to bind to and inhibit caspases, the 
proteases that orchestrate apoptosis, providing a direct explanation for how IAPs 
prevent apoptosis. Importantly, X linked IAP (XIAP), cIAP1 and cIAP2 are shown to 
directly inhibit specific caspases (Devereaux et al., 1997; Roy et al., 1997). This 
differs from the effects of Bcl-2-related apoptotic suppressors, which function at 
points that are distal in the death pathway, upstream of the apoptosome, to prevent 
integration of the caspase-activating signal. 
Structure–function analysis of XIAP showed two distinct domains in XIAP that can 
suppress caspase activity (Devereaux et al., 1999). The BIR3 domain of XIAP binds 
directly to the small (carboxy-terminal) subunit of caspase-9 (Srinivasula et al., 2001). 
The cleavage of caspase-9 is not required for its activation (Stennicke et al., 1999), 
yet, paradoxically, cleavage seems to be required for the inactivation of caspase-9 by 
XIAP. The small subunit of caspase-9 is generated by means of proteolytic cleavage 
at a conserved Asp residue at position 315 — an event that exposes a segment, 
starting at residue 316, that is recognized by the BIR3 domain of XIAP (Srinivasula et 
al., 2001). 
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Fig 1.4 Interaction of IAP with Caspase-3 and -9: The order of XIAP domains starts 
with BIR1 at the amino terminus and terminates with the RING domain at the 
carboxyl terminus. The caspases are shown in their dimeric structure, with large 
subunits in blue-grey, small subunits in blue, and active-site substrate pockets (S-
designation) as yellow dots. The catalytic machinery is between the S1 and S1′ 
pockets (Salvesen and Duckett, 2002). 
 
The mechanism by which XIAP binds to caspase-3 and caspase-7 is entirely different 
to the manner in which it binds caspase-9. The crystallographic resolution of XIAP 
with caspase-3 and caspase-7 shows that the domain in XIAP that is essential for 
interaction lies in a small segment, which is immediately amino-terminal to BIR2 
(Huang et al., 2001; Riedl et al., 2001). This domain functions by reversible, high-
affinity binding to caspase-3 and caspase-7, and results in the steric occlusion of 
normal substrates of these caspases. The crucial sequence in XIAP binds the 
caspase in the opposite orientation to a caspase substrate, and has little requirement 
for the substrate-binding residues in the caspase. So, this important inhibitory domain 
in XIAP binds with high affinity to a surface that is conserved between caspase-3 and 
caspase-7, but XIAP is not a pseudosubstrate and functions solely to mask the active 
site in the caspase (Chai et al., 2001). 
 
1.6.3 Regulation of IAPs 
         Regulation of IAPs is necessary for the occurrence of controlled apoptosis 
which is crucial for modulation of cell number and elimination of damaged cells. IAPs 
are unstable proteins with very short half lives (Hu and Yang, 2003), explaining the 
existence of efficient regulatory mechanisms that control their abundance. They are 
known to be regulated at the transcriptional, post-transcriptional and post-
translational levels by auto-ubiquitination and control of IAP activity by regulatory 
proteins. 
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Transcriptional and post-transcriptional control:  Expression levels of certain IAPs are 
subject to tight transcriptional control. For example, expression of survivin is 
regulated in a cell-cycle-dependent manner, and seems to be induced in normal cells 
at the G2–M boundary (Li et al., 1998). In many situations, the activation of NF-κB 
has been shown to exert a pro-survival effect, and this has been proposed to be 
mediated by the transcriptional activation of one or more genes that encode anti-
apoptotic proteins including cIAP2 (Chu et al., 1997) and XIAP (Stehlik et al., 1998). 
Also, transcriptional upregulation of cIAP2, but not cIAP1 or XIAP was shown under 
severe hypoxia (Dong et al., 2001). 
 
Post-translational control: The highly conserved RING domain at the carboxy termini 
of several mammalian IAPs has a key role in the targeted degradation of proteins by 
the ubiquitin–proteasome system. This process involves the sequential covalent 
addition of ubiquitin, a 76-residue protein; onto specific lysine residues on the target 
protein (Weissman et al., 2001). The RING domains of XIAP, cIAP1 and cIAP2 show 
ubiquitin ligase enzyme (or E3) activity. Targets of IAP-mediated ubiquitination 
include caspases (Huang et al., 2000; Suzuki et al., 2001), Smac/DIABLO 
(McFarlane et al., 2002; Hu et al., 2003) and TRAFs (Li et al., 2002). Importantly, 
IAPs themselves are controlled by auto-ubiquitination leading to degradation (Yang 
et al., 2000). Mammalian IAPs have been reported to form homodimers and 
heterodimers through their RING domains (Silke et al., 2005), which might lead to 
their auto-ubiquitination in trans. The RING domain of IAPs is also found to be 
required for IAP antagonists to induce their degradation (Zachariou et al., 2003). 
  
IAP regulatory proteins: A well studied IAP-interacting molecule is the mitochondrial 
protein Smac/DIABLO (Du et al., 2002; Verhagen et al., 2000). Smac/DIABLO is a 
239-residue protein that is translocated from the inter-membrane space of 
mitochondria to the cytosol, apparently along with Cyt C, in response to an apoptotic 
stimulus. On its release from mitochondria, mature Smac/DIABLO binds XIAP, and 
probably several other IAPs, in a manner that displaces caspases from XIAP. So, 
Smac/DIABLO is a negative regulator of IAP, and is therefore an apoptosis-
enhancing molecule.  
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Smac/DIABLO and several other IAP regulatory proteins like OMI/HTRA2 (Martins et 
al., 2001; Loo et al., 2002) have been found to bind to IAPs through a conserved 
sequence, known as an IAP-binding motif or IBM (Srinivasula et al., 2002) (Fig 1.5).  
 
 
 
 
 
 
 
Fig 1.5  IAP binding motifs (IBMs):  Caspases and many mammallian & insect IAP-
regulatory proteins contain a conserved tetrapeptide sequence that interacts with the 
BIR motifs of IAPs. Also known as RHG (Reaper-Hid-Grim) motif. 
 
1.7 Postconditioning 
               Deleterious manifestations initiated by reperfusion per se are proven to be 
efficiently abrogated by hypoxic pre and postconditioning (Zhao ZQ et al., 2002). 
Events like rapid generation of ROS, activation of sodium hydrogen exchanger, Ca
2+
 
overload and mPTP opening, which are initiated in the first minutes of reperfusion, 
can also trigger later events, such as increased capillary permeability, no-reflow, 
necrosis and apoptosis. The more proximal the position of the above events in the 
time course of reperfusion injury, the greater likelihood that they are effective targets 
for reperfusion therapy, since they tend to attenuate downstream responses as well. 
As stated by Prof. Dr. H. M. Piper ―What comes first must be treated first, as 
otherwise the opportunity for specific treatment is lost‖ (Piper et al., 2004). 
       Postconditioning is controlled reperfusion (Buckberg 1986), defined as a series 
of brief interruptions of ischemia/hypoxia applied at the very onset of reperfusion. The 
concept of postconditioning was first revealed in 2002 by Vinten-Johansen and 
colleagues. The first studies published by Zhao et al., (2002) and Halkos et al., 
(2004) from this group compared postconditioning to the gold standard 
cardioprotective strategy of ischemic preconditioning. Using a canine model of one 
hour of left anterior descending (LAD) coronary artery occlusion and three hours of 
reperfusion, one group was assigned to abrupt coronary artery reflow while the other 
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was assigned to postconditioning using an algorithm of 30 seconds LAD reperfusion 
and 30 seconds re-occlusion, repeated for three cycles. Full reflow was continued for 
the remainder of the three hours. A third group of canines was preconditioned by a 
single 5 minute LAD occlusion followed by 10 minutes of reperfusion prior to the 
prolonged ischemic period. As expected, ischemic preconditioning reduced infarct 
size by approximately 40% compared to controls and surprisingly, the infarct size 
observed with the postconditioning algorithm was comparable to that observed with 
ischemic preconditioning. The infarct size reduction was confirmed by plasma 
creatine kinase activity at the end of reperfusion. Neutrophil accumulation (tissue 
myeloperoxidase (MPO) activity) in the area at risk in both the ischemic 
preconditioning and the postconditioning groups was significantly reduced compared 
to untreated controls. Postconditioning also preserved post-ischemic coronary artery 
endothelial function (vasorelaxation to endothelium-dependent stimulators of nitric 
oxide synthase) comparable to that observed with preconditioning. The surface 
expression of P-selectin on coronary artery vascular endothelium was comparably 
attenuated with both preconditioning and postconditioning, suggesting a reduction in 
the pro-inflammatory state of the coronary artery endothelium. Furthermore, 
superoxide radical generation by the endothelium of the postischemic LAD was less 
in postconditioned groups than in controls subjected to abrupt coronary artery 
reperfusion. The comparable reduction in tissue edema observed in both 
preconditioning and postconditioning groups is commensurate with an attenuation of 
vascular endothelial activation and dysfunction. It was also observed that oxidant 
generation by the postischemic myocardium at the end of reperfusion, measured by 
dihydroethidium fluorescence, was reduced with postconditioning in both 
parenchyma and vascular/perivascular tissue, suggesting a reduction in the oxidant 
burden in reperfused tissue (Zhao et al., 2002). The plasma lipid peroxidation product 
malondialdehyde was accordingly reduced comparably in preconditioned and 
postconditioned groups, consistent with reduced oxidant generation. Additionally, 
Halkos et al., (2004) also reported that postconditioning reduced the incidence of 
reperfusion arrhythmias, a finding that was confirmed by Galagudza et al., (2004) in 
isolated perfused rat hearts. 
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1.7.1 Triggers and mediators of postconditioning 
 
Adenosine: Endogenously released adenosine is involved in the cardioprotection of 
postconditioning. It has been shown that the release of endogenous adenosine into 
the buffer perfusate of isolated mouse hearts was delayed during postconditioning 
(Kin et al., 2004). Additionally, in a rat model of coronary artery occlusion-reperfusion, 
blockade of adenosine receptors with 8-sulfophenyl theophylline administered 
intravenously five minutes before reperfusion reversed the infarct reduction observed 
with postconditioning. This was also observed in an in situ rabbit model of coronary 
artery occlusion-reperfusion (Philipp et al., 2004). The cardioprotective actions of 
adenosine during postconditioning were linked to activation of the adenosine A2A 
and A3 receptors, but not the A1 receptor subtype (Kin et al., 2005). Interestingly, the 
physiological effects of adenosine reperfusion therapy essentially recapitulate those 
observed for postconditioning (Zhao et al., 1993; Jordan et al., 1997). Therefore, 
higher concentrations of endogenous adenosine may act as a trigger of 
cardioprotection, potentially through its interactions with adenosinergic G-protein 
coupled receptors to attenuate the release of oxidants and cytokines by activated 
endothelium and myocytes, in addition to its well-known inhibitory effects on 
neutrophils. 
 
KATP channels:  The adenosine triphosphate-sensitive potassium (KATP) channels are 
activated during postconditioning (Yang et al., 2004). Blockade of KATP channels with 
the nonselective inhibitor, glibenclamide, abrogated the infarct sparing effect of 
postconditioning. Further, the selective inhibitor of mitochondrial KATP channel 
activation, 5-hydroxydecanoate, also reversed the infarct sparing effect of 
postconditioning, suggesting that protection involved specific activation of the 
mitochondrial KATP channels. However, it was not shown whether the sarcolemmal 
KATP channel had any role, parallel or synergistic. 
  
Nitric oxide: Nitric oxide synthase (NOS) is reported to be involved in the protective 
effect of postconditioning (Yang et al., 2003). Blocking NOS with L-NAME 
administered just before reperfusion alone had no effect on infarct size, but in 
conjunction with postconditioning, L-NAME completely inhibited the infarct-sparing 
effects of postconditioning. The involvement of the endothelial isoform (e-NOS) is 
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supported by a reported increase in phospho-eNOS seven minutes after reperfusion 
with postconditioning compared to abrupt reperfusion in isolated perfused rat hearts 
(Tsang et al., 2004). In addition, postconditioning could be blocked by L-NAME and 
the guanylyl-cyclase inhibitor 1H-[1,2,4]oxadiazolo- [4,3-a]quinoxaline-1-one (ODQ), 
suggesting an NO – cGMP pathway (Pagliaro et al., 2004). NOS may be involved at 
several levels in ischemia/reperfusion. The release of NO by coronary vascular 
endothelium is impaired after ischemia/reperfusion (Guo et al., 1996; Ma et al., 
1993). Although not shown directly, postconditioning may reverse the NO release, 
speculated by attenuated P-selectin expression, decreased neutrophil adherence, 
and improved vasodilator responses to acetylcholine observed after postconditioning 
in canine models (Halkos et al., 2004; Zhao et al., 2003), all of which are 
physiological responses associated with increased NO generation. eNOS is also a 
downstream target of PI3 kinase – Akt pathway and other reperfusion injury kinase 
pathways (Hausenloy et al., 2004), which were shown to be involved in 
postconditioning. 
  
mPTP: The mitochondrial permeability transition pore is one of the most important 
mediator of cardioprotection elicited by postconditioning. This selectively permeable 
pore remains closed during ischemia, but opens during the first few minutes of 
reperfusion (Griffiths et al., 1995; Halestrap et al., 1998). Opening of the mPTP has 
been associated with onset of cell death by both necrosis and apoptosis. 
Accordingly, inhibition of mPTP opening has been shown to be cardioprotective 
(Hausenloy et al., 2003). Postconditioning does inhibit opening of the mPTP (Argaud 
et al., 2005). This would be consistent with the involvement of NO, which inhibits 
mPTP opening (Piantadosi et al., 2002), reduced oxidant burden and reduced 
intracellular and mitochondrial Ca
2+
  (Sun et al., 2005). Taken together, inhibition of 
mPTP opening, generation of NO, reduction of ROS and Ca
2+
 and activation of 
several possible signaling molecules are major contributors of the cardioprotection 
mediated by postconditioning. 
 
1.7.2. Signaling pathways in postconditioning 
              A number of signal transduction pathways have been shown to be recruited 
by postconditioning, which mostly converge at the mitochondria and are pivotal to the 
cardioprotection elicited.   
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Akt (Tsang et al., 2004) and ERK 1/2 (Yang et al., 2003) pathways are the first 
among these, providing the first line of evidence that postconditioning is capable of 
recruiting pro-survival signal transduction cascades. In these studies, PD98059 and 
LY294002 / Wortmannin, inhibitors of ERK1/2 and Akt pathway respectively, were 
shown to reduce the infarct sparing effect of postconditioning. Akt and ERK1/2 
pathways together were subsequently named as RISK or reperfusion-induced 
survival kinase pathway (Hausenloy et al., 2004). Although the actual mechanism 
through which the RISK pathway is recruited by postconditioning is unresolved, 
experimental data suggest the activation of cell-surface receptors, including the 
adenosine A2 receptor (Morrison et al., 2007). The down stream targets of RISK- 
mediated protection are clearer and converge on the mitochondria. The 
phosphorylation and thus inhibition of GSK-3β, known to elicit cardioprotective effects 
via inhibition of mPTP opening (Juhaszova et al., 2004), is reported to occur in 
postconditioning (Gomez et al., 2008).  
The roles of p38 MAPK and the JNK pathway in postconditioning have been much 
debated (Hausenloy et al., 2006; Bassi et al., 2008). One study shows the inhibition 
of JNK and p38 MAPK in postconditioning (Sun et al., 2006), indicating that activation 
of these pathways is detrimental to cardioprotection. Other signal transduction 
pathways involved in postconditioning include the JAK-STAT pathway (Boengler et 
al., 2008; Goodman et al., 2008), sphingosine kinase 1 (Jin et al., 2008) and protein 
kinase C (Penna et al., 2006). Sphingosine kinase 1 was infact demonstrated to have 
an obligatory role in postconditioning, which is potentially upstream to the RISK 
pathway (Jin et al., 2008) 
           Taken together, postconditioning is not only as powerful as preconditioning, 
but infact seems to be a comparatively better strategy, since it has the potential of 
being clinically applicable in the most common situation of unexpected coronary 
occlusion and acute myocardial infarction. The clinical usage of the maneuver gained 
further acclaim since the application of postconditioning to human heart following 
acute myocardial infarction (Laskey et al., 2005).  
 
1.8 Aims and objectives of the project 
      The present study aims to examine the effect of postconditioning on hypoxia-
reoxygenation induced endothelial apoptosis. Coronary endothelial apoptosis, 
preceding myocyte apoptosis, is a critical event in reperfusion injury. 
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Postconditioning, a strategy known to effectively reduce reperfusion injury, is well 
proven in cardiomyocytes, However, little is known about postconditioning in 
endothelial cells and whether it plays a role in anti-apoptosis. The project aims to 
study the anti-apoptotic effect of postconditioning in endothelial cells and the 
molecular mechanisms involved, focusing on the inhibitors of apoptosis proteins 
(IAPs) as potential antiapoptotic candidates induced by hypoxia. More specifically, 
the following questions were addressed; 
 
 What is the effect of postconditioning on hypoxia/reoxygenation-induced 
endothelial apoptosis? 
 What are the anti-apoptotic proteins involved? 
 What is their mechanism of action? 
 Which signal transduction pathways might be recruited? 
        
       The study was performed using cultured human umbilical vein endothelial cells 
(HUVEC), that were subjected to hypoxia-reoxygenation and/or postconditioning. 
Apoptosis was measured by Annexin V staining in flow cytometry and caspase-3 
cleavage in Western blotting. Downregulation with siRNA and pharmacalogical 
inhibition were employed to determine the molecular and signaling mediators 
involved. Co-immunoprecipitation and co-localization studies were performed to 
analyze the interaction of proteins. An intact vessel model of rat aorta was 
established to demonstrate the physiological relevance of the molecules identified to 
be involved in the anti-apoptotic effect of endothelial postconditioning.  
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2. Materials 
   
2.1 Chemicals and reagents 
 
All chemicals used were of the highest analytical purity and best quality available. 
 
Acrylamide Roth, Karlsruhe 
Agarose Invitrogen, Paisley, United Kingdom 
6-Aminohexanoic acid Merck-Schuchardt, Hohenbrunn 
APS Serva, Heidelberg 
Benzonase Merck, Darmstadt 
Bisacrylamide Roth, Karlsruhe 
Bromphenol blue Sigma, Deisenhofen 
BSA Sigma, Deisenhofen 
Calcium chloride Merck, Darmstadt 
Collagenase PAA Laboratories, Pasching, Austria 
CWFSG Sigma, Deisenhofen 
Di-Sodium hydrogen phosphate  Roth, Karlsruhe 
DMSO Stigma, Deisenhofen 
DTT Stigma, Deisenhofen 
Dynabeads protein G Invitrogen, Karlsruhe 
EC Oxyrase                                              Oxyrase, Mansfield, USA 
EDTA-Sodium chloride Sigma, Deisenhofen 
Endothelial growth medium kit PromoCell, Heidelberg 
Ethanol Riedel de Haёn, Seelze 
FCS PAA Laboratories, Pasching, Austria  
Filter paper Biotec-Fischer, Reiskirchen 
Glucose Merck, Darmstadt 
Glycerine Roth, Karlsruhe 
HBSS PAA Laboratories, Pasching, Austria 
HEPES Roth, Karlsruhe 
High molecular weight standard Sigma, Deisenhofen 
Isoflurane                                                 Baxter, Unterschleißheim 
Low molecular weight standard Sigma, Deisenhofen 
Magnesium chloride Fluka, Neu-Ulm 
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Magnesium sulfate Merck, Darmstadt 
Methanol Riedel de Haёn, Seelze 
Mercaptoethanol Merck-Suchard, Hohenbrunn 
NCS PAA Laboratories, Pasching, Austria 
Nitrocellulose membrane Schleicher und Schuell, Dassel 
Page Ruler Fermentas, St.Leon-Rot 
Paraformaldehyde Merck, Darmstadt 
Penicillin-streptomycine Gibco BRL, Eggenstein 
Ponceau S solution Serva, Heidelberg 
Potassium chloride Merck, Darmstadt 
Potassium  dihydrogen phosphate Merck, Darmstadt 
Protease inhibitor cocktail Complete Roche Diagnostics, Mannheim 
Protein blockt serum-free  Dako, Hamburg 
Skimmed milk powder Applichem, Darmstadt 
Sodium bicarbonate  Merck, Darmstadt 
Sodium chloride Roth, Karlsruhe 
Sodium hydroxide Roth, Karlsruhe 
Sodium dodecyl sulphate Merck, Darmstadt 
Sodium flouride Merck, Darmstadt 
Super Signal-West Pierce, Niedderau 
TEMED Sigma, Deisenhofen 
Tissue Tek Sakura Finetek, Staufen 
Tris Roth, Darmstadt 
Triton X 100 Serva, Heidelberg 
Trypsin-EDTA solution Biochrom AG, Berlin 
Tween 20 Amersham, Braunschweig 
 
2.2 Pharmacalogical inhibitors 
 
LY294002 Calbiochem, Bad Soden  
PD98059 Calbiochem, Bad Soden 
SB203580  Calbiochem, Bad Soden 
SP600125 Sigma, Steinheim 
UO126  Calbiochem, Bad Soden 
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2.3 Antibodies 
 
Primary antibodies: 
Anti-Actin (mouse IgG) Sigma, Deisenhofen  
Anti-Akt~p (rabbit IgG) Cell Signaling Technology, USA 
Anti-cIAP1 (goat IgG) Santa Cruz biotechnology, Heidelberg 
Anti-cIAP2 (rabbit IgG) Santa Cruz biotechnology, Heidelberg 
Anti-c-jun~p (rabbit IgG) Cell Signaling Technology, USA 
Anti-cleaved Caspase-3 (rabbit IgG) Cell Signaling Technology, USA 
Anti-ERK1/2~p (mouse IgG) Cell Signaling Technology, USA  
Anti-p38 MAPK~p (mouse IgG) Cell Signaling Technology, USA 
Anti-procaspase-3 (mouse IgG) Imgenex, Darmstadt 
Anti-vinculin (mouse IgG)    Sigma, Steinheim 
Anti-von Willebrand Factor (rabbit IgG)  Dako, Hamburg 
Anti-XIAP (rabbit IgG)   Cell Signaling Technology, USA 
 
Secondary antibodies: 
Anti-goat IgG HRP-conjugated Dianova, Hamburg 
Anti-mouse IgG HRP-conjugated Amersham, Freiburg 
Anti-rabbit IgG HRP-conjugated  Amersham, Freiburg 
Anti-mouse IgG Alexa 633-conjugated Invitrogen, Karlsruhe 
Anti-rabbit IgG Alexa 488-conjugated Invitrogen, Karlsruhe 
Anti-rabbit IgG Alexa 546-conjugated                      Invitrogen, Karlsruhe 
 
2.4      SiRNA transfection 
 
cIAP2 siRNA Santa Cruz biotechnology, Heidelberg                                     
Control siRNA                                                  Eurogentec, Cologne  
JetSI Endo                                                       Eurogentec, Cologne 
Opti-MEM                                                         Invitrogen, Karlsruhe 
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2.5   Flow cytometry 
  
AnnexinV/PI-FITC kit BD Pharmingen, Heidelberg 
FACS Clean BD Pharmingen, Heidelberg 
FACS Flow BD Pharmingen, Heidelberg 
FACS Rinse BD Pharmingen, Heidelberg 
FACS tubes BD Biosciences, Heidelberg 
 
2.5 Laboratory instruments 
 
CCD camera  Bio Rad, Hercules, USA 
Culture dishes Becton-Dickinson, Heidelberg 
Demineralisation unit Millipore, Eschborn 
Electroblot chamber Biotec-Fischer, Reiskirchen 
Electrophoresis chamber Biotec-Fischer, Reiskirchen 
Electrophoresis apparatus Biometra, Göttingen 
FACS Calibur flowcytometer® BD Biosciences, Heidelberg 
Glass articles Schott, Mainz 
Glass coverslips Menzel, Braunschweig 
Hamilton syringe Hamilton, Bonaduz, Switzerland 
Incubator Heraeus,Hanau 
LSM-510 confocal microscope Carl-Zeiss, Heidelberg 
Magnetic rack Dynalbiotech ASA Oslo, Norway 
Magnet stirrer Jahnke und Kunkel, Staufen 
Microscope Olympus, Japan 
Neubauer-chamber Superior, Marienfeld 
pH-Meter WTW-Weilheim  
Pipettes Eppendorf Netheler-Hinz, Hamburg 
Pipette tips Eppendorf Netheler-Hinz, Hamburg 
Power supply Biometra, Göttingen 
Shaker Biometra, Göttingen 
Sterile bench Heraeus, Hanau 
Sterile filter (0.2 µm) Sartorius, Göttingen 
Sterile pipettes Becton-Dickinson, Heidelberg 
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Table centrifuge Hereaus, Hanau 
Tubes Eppendorf-Netheler-Hinz, Hamburg 
Vortex Heidolph, Kehlheim 
Water bath Julabo, Seelbach 
 
2.6  Software 
Cell-Quest-Pro BD Biosciences, Heidelberg 
LSM 510 Carl-Zeiss, Heidelberg 
Quantity One analysis software Bio Rad, Hercules, USA 
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3.        Methods 
 
3.1 Preparation of human umbilical vein endothelial cells 
 
Collagenase solution: 
HBSS x ml 
Collagenase II (293 Units/mg) (wt/vol)          0.025% 
MgCl2. 6 H2O        0.5 mM 
CaCl2            1.5 mM 
 
Cell culture medium: 
Endothelial cell basal medium x ml 
FCS (vol/vol) 10% 
penicillin/streptomycin (vol/vol) 2% 
ECGS/Heparin (wt/vol) 0.4% 
Hydrocortisone (wt/vol) 0.1% 
Basic fibroblast factor 1 ng/ml 
Epidermal growth factor 0.1 ng/ml 
 
Protocol: The procedure conforms to the principles outlined in the ‗‘Declaration of 
Helsinki‘‘ (Cardiovascular Research 1997; 35:2–3). Human umbilical vein endothelial 
cells (HUVEC) were isolated from freshly collected umbilical cords according to Jaffe 
et al., (1973) with minor modifications. After cleaning, the untraumatized umbilical 
vein was canulated and perfused with HBSS to remove traces of blood. The lumen of 
the vein was then filled with collagenase solution and incubated for 20 min at 37° C.  
After incubation, the collagenase solution containing endothelial cells was removed 
by perfusing the vein with 30 ml of HBSS containing 3% (vol/vol) FCS, added to 
inactivate collagenase. The effluent was collected in a 50 ml falcon tube and 
centrifuged for 5 min at 250 x g at RT. The supernatant was discarded and the cell 
pellet was resuspended in culture medium containing 0.1% (vol/vol) 
penicillin/streptomycin. Thereafter, cells were seeded onto 3-4 primary culture dishes. 
After incubation for 2 h at 37° C and 5% CO2 cells were extensively washed with 
HBSS to remove the unattached non-endothelial cells and cell debris. Adherent cells 
were incubated in 15-20 ml of cell culture medium containing 2% (vol/vol) 
 35 
penicillin/streptomycin at 37° C and 5% CO2. After 24 h the medium was replaced 
with fresh cell culture medium. 
 
3.2 Subcultivation of endothelial cells 
 
Confluent monolayers of primary endothelial cell cultures were trypsinized 5 to 7 days 
after isolation. Cells were washed with HBSS and subsequently incubated with 3 ml 
of trypsin/EDTA solution (composition in mM: 137 NaCl, 2.7 KCl, 1.5 KH2PO4, 8.0 
Na2HPO4, pH 7.4, 0.05% (wt/vol) trypsin and 0.02% (wt/vol) EDTA). Trypsinized cells 
were collected into cell culture medium and seeded at a density of 5.5 x104 cells/cm2 
on 35 mm2 or 60 mm2 dishes, according to the experiment being performed. For 
immunostaining and confocal microscopy cells were seeded on 25 mm2 glass cover 
slips. Experiments were performed with confluent endothelial monolayers of either 
primary or passage 1, 3-4 days after seeding. 
 
3.3   Experimental protocol for hypoxia/reoxygenation and postconditioning 
 
Subconfluent monolayers of HUVEC were subjected to severe hypoxia (Po2 < 1 
mmHg) for 2 h followed by 24 h of reoxygenation. Hypoxia was applied with 1U/ml 
EC Oxyrase, a biocatalyst capable of consuming molecular oxygen in the presence 
of an available hydrogen donor (Jacobson et al., 1987). Following the hypoxic phase, 
postconditioning was applied at the onset of reoxygenation by the intermittent 
application of three short periods of severe hypoxia, 5 min each, separated by a 5 
min reoxygenation period (see below). For this, endothelial monolayers were 
incubated with regular growth medium containing 1U/ml EC Oxyrase, thrice for 5 min, 
interrupted by 3 periods of incubation with Oxyrase-free medium, 5 min each. 
Oxyrase-free medium was used during all the 6 incubation periods for control 
samples, to nullify the effects of medium change.  
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3.4 siRNA transfection of endothelial cells 
Downregulation of cIAP2 was achieved by transfecting endothelial cells with cIAP2 
specific siRNA duplexes ordered from Santa Cruz Biotechnolgy. The calculations 
given below are for subconfluent HUVEC monolayers seeded on 30 mm
2
 dishes.  
Solution A: X (X = siRNA in ng x 0.003) µl of JetSI-ENDO in 100µl Opti-MEM 
Solution B: 2.5µl (25 nM) of siRNA in 100µl Opti-MEM 
Protocol: 24 h prior to the application of hypoxia/reoxygenation or postconditioning, 
70 - 80 % confluent cell monolayers were transfected with cIAP2 specific siRNA for 
5.5 h according to the manufacturer‘s instructions. For this, cells were washed and 
incubated in a low-serum transfection medium, Opti-MEM, since serum hinders the 
uptake of siRNA by the cells. Solution A containing the transfection reagent, Jet SI-
ENDO is then added to solution B containing siRNA by gentle vortexing. The mixture 
was incubated for 30 min to allow formation of complexes and is then gently added to 
the cells drop-wise. After 5.5 h of incubation, the low-serum transfection medium is 
replaced with regular medium allowing normal growth for 16-18 h. Control samples 
were treated with the same concentration of non-specific control siRNA following the 
same protocol. 
 
3.5 Application of pharmacological inhibitors 
 
PI3 kinase inhibitor  LY 294002  10 µM 
ERK 1/2 inhibitor  PD 98059            20 µM  
ERK 1/2 inhibitor  UO 0126             10 µM  
p38 MAPK inhibitor  SB 203580          10 µM 
JNK inhibitor   SP600125            10 µM 
 
Stock solutions were prepared immediately before use in basal medium with DMSO. 
Appropriate volumes of these solutions were added to the cells yielding a final 
solvent concentration of ≤ 0.1% (vol/vol), 30 min prior to the experiment. The same 
final concentrations of DMSO were included in all respective control experiments. 
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3.6 Fluorescence-activated cell sorting (FACS) analysis 
 
Effect of hypoxia/reoxygenation and postconditioning on endothelial cell apoptosis 
was determined by FACS analysis of annexin V-FITC and propidium iodide staining 
according to the manufacturer‘s instructions. Annexin V and PI were added to 
trypsinized and suspended endothelial cells which were analyzed by flow cytometry 
on a FACS Calibur using Cell Quest Pro software. Cells that were annexin-FITC 
positive were identified as apoptotic, while cells that were PI positive and Annexin-
FITC negative were categorized as necrotic. Non-stained cells were identified as 
vital. 
3.7 Protein analysis 
3.7.1   Preparation of Samples 
Lysis buffer: 
Tris/HCl pH 6.8  250 mM 
Glycerol                              20 % (vol/vol) 
SDS                                    4 % (wt/vol) 
β-mercaptoethanol             1 % (vol/vol) 
Bromphenol blue                0.001 % (wt/vol)  
DTT                                    10 mM (added freshly before use) 
Benzonase®                      50 IU/ml (added freshly before use) 
MgCl2                                 2 mM (added freshly before use) 
 
Protocol: Endothelial cells were washed with HBSS and subsequently lysed in 150 μl 
of preheated 2X SDS lysis buffer. Subsequently, 50 IU/ml Benzonase® and 2 mM 
MgCl2 were added and lysate was collected in a 1.5 ml Eppendorf tube. Samples 
were denatured for 3 minutes at 95 °C and used immediately or stored at –20 °C. 
 
3.7.2    SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Resolving gel buffer:  Tris/HCl; pH 8.8 120 mM 
Stacking gel buffer:   Tris/HCl; pH 6.8 120 mM 
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10X Gel running buffer:  
Tris   250 mM 
Glycine 2.0 M 
SDS  10 % (wt/vol) 
 
 
SDS gels: 
  
Resolving gels 
 
Stacking gel 
 
Percentage 
 
12.5 % 
 
15 % 
 
6 % 
 
Acrylamide 
Bisacrylamide 
Millipore water 
Resloving gel buffer 
Stacking gel buffer 
SDS 10% ( wt/vol ) 
TEMED 
APS 10% ( wt/vol ) 
 
12.7 ml 
7.0 ml 
9.8 ml 
9.5 ml 
-------- 
0.4 ml 
30 µl 
0.4 ml 
 
15.3 ml 
8.4 ml 
5.8 ml 
9.5 ml 
-------- 
0.4 ml 
30 µl 
0.4 ml 
 
3.8 ml 
2 ml 
17.5 ml 
-------- 
6.0 ml 
0.25 ml 
20 µl 
0.25 ml 
 
 
Protocol: After cleaning the glass plates and spacers with water and ethanol, the gel 
apparatus was assembled and the resolving gel solution was poured (~ 10 cm 
height), and layered with water. The gel was let to polymerize for 3-4 h or overnight at 
room temperature. The layer of water was removed and the stacking gel solution was 
poured on top of the resolving gel, followed by the insertion of a comb. The stacking 
gel was let to polymerize for 1 h at room temperature. After removing the comb, 1X 
running gel buffer was added to the chamber and the wells were washed with a 
syringe. Protein samples were loaded into the wells and the gel was run overnight at 
45 volts. The run was stopped when bromophenol blue had passed through the gel. 
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3.7.3 Western blotting  
 
Proteins separated by SDS-PAGE were transferred onto a nitrocellulose membrane 
by semi-dry blotting. Afterwards proteins of interest were immunodetected using 
specific antibodies. 
Solutions and materials: 
• Nitrocellulose transfer membrane, cut to the dimensions of the gel 
• Six pieces of Whatman® 3 MM filter paper, cut to the dimensions of the gel 
• Blotting chamber 
• Anode buffer 1: 0.3 M Tris/HCl; pH 10.4, 20% (vol/vol) methanol 
• Anode buffer 2: 30 mM Tris/HCl; pH 10.4, 20% (vol/vol) methanol 
• Cathode buffer: 25 mM Tris/HCl; 40 mM 6-amino-n-hexanoic acid; pH 9.4, 20%         
   (vol/vol) methanol  
 
Protocol: The blotting chamber was assembled as follows: Two sheets of filter paper 
(Whatman® 3MM) soaked in anode buffer 1, were placed onto the centre of the 
graphite anode of the blotting chamber. On top of these sheets, two sheets of filter 
paper, soaked in anode buffer 2, were placed followed by nitrocellulose membrane 
equilibrated in anode buffer 2 for 10-15 min. After briefly equilibrating with cathode 
buffer, the SDS-gel (devoid of stacking gel) was layered on top of the nitrocellulose 
membrane, avoiding air bubbles. Two sheets of filter paper, pre-soaked in cathode 
buffer, were then placed on top of the gel followed by the graphite cathode of the 
blotting chamber. Transfer was achieved by application of 0.8-0.9 mA /cm
2
 current 
for approximately 2- 2.5 h. 
 
3.7.4 Staining of transferred proteins 
  
To estimate the efficiency of protein transfer after blotting, the membrane was stained 
with ponceau S, a reversible stain that produces pink bands on a light background. 
The nitrocellulose membrane was washed with Millipore water for 1 min, incubated in 
Ponceau-S solution for 2-3 min with constant shaking at room temperature. 
Subsequently the membrane was destained by washing in Millipore water to the 
desired contrast and photographed. To remove the stain completely, the membrane 
was washed with TBST (1X TBS plus 0.1% Tween 20) under constant shaking. 
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3.7.5 Immunodetection of proteins 
 
Solutions: 
10X Tris-buffered saline (TBS): 100 mM Tris/HCl (pH 7.4), 1.6 M NaCl  
TBS Tween (TBST): 1X TBS, 0.1% (vol/vol) Tween 20 
Blocking-buffer and antibody-dilution buffer: 
3% (wt/vol) BSA in 1X TBST or 5% (wt/vol) non-fat dried milk powder in 1X TBST 
 
Primary Antibodies: 
 
Antibody                                                 Dilution                                      Dilution buffer 
Anti-Actin (mouse IgG)   1:1000    BSA 
Anti-cIAP1 (goat IgG)                             1:500                                           BSA 
Anti-cIAP2 (rabbit IgG)                           1:2000                                         BSA 
Anti-cleaved caspase-3 (rabbit IgG)       1:1000                                        BSA 
Anti-phospho Akt (rabbit IgG)                 1:1000                                         Milk 
Anti-phospho c-jun (rabbit IgG)               1:1000                                         BSA 
Anti-phospho ERK1/2 (mouse IgG)         1:2000                                         BSA 
Anti-procaspase-3 (mouse IgG)              1:1000                                        BSA 
Anti-vinculin (mouse IgG)                        1:1000                                         BSA 
Anti-XIAP (rabbit IgG)                             1:1000                                         Milk 
 
Secondary antibodies, horseradish peroxidase (HRP)-labeled: 
 
Antibody                                                  Dilution                             Dilution buffer 
Anti-rabbit IgG    1:2000   BSA or Milk 
Anti-mouse IgG                                       1:2000   BSA or Milk 
Anti-goat IgG                                           1:1000   BSA or Milk 
 
Protocol: After a brief washing with Millipore water and TBST, the membranes were 
blocked with either 5% (wt/vol) non-fat milk powder or 3% (wt/vol) BSA in TBST for 2 
h at room temperature. After blocking, the membranes were incubated with primary 
antibody overnight at 4 °C, followed by washing with TBST 3-4 times for 5-10 
minutes each time at room temperature and incubated with secondary antibody for 1 
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h at room temperature. The membranes were then washed with TBST 3-4 times for 
10-15 min each and incubated with enhanced chemiluminescence (ECL) solution (30 
sec to 1 min) and the luminescence was detected and recorded with Bio-Rad 
Quantity One gel documentation system. 
 
3.7.6 Stripping and reprobing 
 
Stripping solution:  (50 ml) 
Millipore H2O                   44 ml 
1M Tris HCl (pH 6.8)       3.1 ml 
10% SDS (wt/vol)  2.5 ml 
 
To reprobe the membranes with antibodies against other proteins of the same or 
equal size, bound antibodies were removed by incubating the membranes with 
prewarmed (60°C) stripping buffer 2-5 min at RT under constant shaking. 
Subsequently membranes were washed extensively with TBST buffer, blocked and 
reprobed with appropriate antibodies. 
 
3.8 Co-immunoprecipitation 
 
To determine the binding of cIAP2 with procaspase-3 under conditions of 
hypoxia/reoxygenation and postconditioning, co-immunoprecipitation was performed 
with procaspase-3 coated G protein dynabeads. 
 
Solutions and materials: 
G protein coated magnetic beads:         6 µl beads suspention / ~ 1mg total cell lysate 
Anti-procaspase-3 antibody:                  3 µg / ~ 1 mg total cell lysate 
 
Sodium phosphate buffer (0.1M) pH 7.4: 
Na2HPO4 80 mM 
NaH2PO4                                       20 mM 
 
Phospahate Buffer Saline (PBS) pH 7.4: 
NaCl     137 mM 
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KCl      2.7 mM 
KH2PO4     1.5 mM 
Na2HPO4     8.0 mM 
 
Lysis Buffer (ice cold): 
Tris/HCl (pH 7.5)     50 mM 
NaCl     150 mM 
Triton X-100      50 mM  
NaF         1 mM  
EDTA         1 mM  
EGTA     150 mM 
Na3VO4     0.5 mM  
PMSF (vol/vol)        0.5% 
NP-40 (vol/vol)        0.5% 
1 tablet proteinase inhibitor CompleteTM per 10 ml buffer 
 
Preparation of beads: Protein G-coated magnetic beads were washed 3-4 times with 
0.1 M sodium phosphate buffer using a magnetic rack and incubated with anti-
procaspase-3 antibody overnight at 4 °C with end-over-end rotation. The antibody 
coated beads were blocked with 6% (wt/vol) skimmed milk powder in 0.1 M sodium 
phosphate buffer and 0.1% (vol/vol) tween 20 for 1 h at room temperature. 
Afterwards the beads were washed 3-4 times with 0.1 M sodium phosphate buffer 
containing 0.1 % (vol/vol) Tween 20 and stored in 50 μl of 1X PBS. 
 
Protocol: Confluent endothelial monolayers cultured on a 10 cm cell culture dish that 
were subjected to hypoxia/reoxygenation or postconditioning were incubated with 
600 μl lysis buffer for 10 minutes on ice and subsequently harvested by scraping with 
a rubber policeman. Cells were further lysed in a douncer or using a 25 g needle and 
syringe. The lysate was centrifuged at 1000 X g for 2 min at 4 °C. The cleared 
supernatant was added to the antibody coated beads and incubated for 1.5 h at 4 °C 
with end-over-end rotation. Supernatant containing unbound protein was discarded 
and the beads were washed three times with PBS containing 0.1 % (vol/vol) Tween 
20, followed by heating with 2X SDS lysis buffer for 5 min at 90 °C to detach the 
bound protein. The dissolved protein in buffer was analyzed by SDS-PAGE. 
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3.9 Immunofluorescence: 
 
Solutions and materials: 
 
Primary antibodies: 
 
 
Antibody 
 
Cell culture  
 
Aorta sections 
 
 
 
Dilution 
 
Dilution buffer 
 
Dilution 
 
Dilution buffer 
 
Anti-cIAP2 (rabbit IgG) 
 
Anti-procaspase-3  
(mouse IgG) 
 
Anti-von Willebrand factor 
(rabbit IgG) 
 
1:500 
 
1:500 
 
 
------ 
 
BSA+CWFSG 
 
BSA+CWFSG 
 
 
----------- 
 
1:50 
 
1:50 
 
 
1:50 
 
Protein block 
 
Protein block 
 
 
Protein block 
 
 
 
Secondary antibodies: 
  
 
Antibody 
 
Cell culture  
 
Aorta sections 
 
 
 
Dilution 
 
Dilution buffer 
 
Dilution 
 
Dilution buffer 
 
Anti-mouse  
Alexa fluor 488  
 
Anti-rabbit  
Alexa fluor 633 
 
Anti-rabbit 
Alexa fluor 546 
 
 
1:500 
 
 
1:500 
 
 
------ 
 
BSA+CWFSG 
 
 
BSA+CWFSG 
 
 
----------- 
 
----- 
 
 
----- 
 
 
1:250 
 
--------- 
 
 
--------- 
 
 
 Protein block  
 
 
 
Buffered glycerol:  
Na2CO3 1.5 M 
NaHCO3                                  1.5 M 
Glycerol (water-free) 
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1.5 M NaHCO3 solution is slightly heated and set to a pH of 8.6 using 1.5 M Na2CO3 
solution. 1 portion of the above buffer is then mixed with 1 portion of glycerol.  
 
Protocol: Endothelial monolayers on glass cover slips were washed with 1X PBS and 
fixed with 4 % (wt/vol) paraformaldehyde at 37 °C for 20 min, followed by 
permeabilization with 0.1 % (wt/vol) Triton X-100 at 37 °C for 20 min. Cells were then 
washed 3-4 times with 1X PBS and blocked with 5 % (wt/vol) bovine serum albumin 
+ 5 % (wt/vol) cold water fish skin gelatin for 1 h to prevent non-specific binding. 
Tissue sections were blocked similarly with Protein block serum-free. Samples were 
then probed with primary antibody (1:50 dilution for tissue sections and 1:500 dilution 
for cells) overnight at 4 °C, followed by thorough washing in 1X PBS. Secondary 
antibodies tagged with Alexa fluor 488/ Alexa fluor 546/ Alexa fluor 633 were used in 
a dilution of 1: 250 – 1:500 for 1 h at room temperature. The samples were then 
washed 3-4 times with 1X PBS and mounted with buffered glycerol. Immunoreactivity 
was visualized and analyzed by confocal microscopy with Carl Zeiss LSM 510. 
 
3.10    Intact vessel model 
 
Zamboni fixative (pH 7.3): 
Paraformaldehyde:    20 mg 
Picric acid (saturated solution):  150 ml 
 
The solution is heated to 60°C and alkalized with 2.5% (vol/vol) NaOH until the 
solution is clear and made upto 1 litre with phosphate buffer (80 mM NaH2PO4; 20 
mM Na2HPO4). 
 
Protocol: Freshly excised aortas were cleaned and rinsed with 1X PBS and 
immersed in a 2 ml Eppendorf tube containing PromoCell growth medium. Hypoxia 
was applied following the same protocol used for cell cultures, by flushing the 
medium with 1U/ml of EC oxyrase. Postconditioning was applied at the onset of 
reoxygenation after 2 h of hypoxia, while control vessels were normally reoxygenated 
with EC-oxyrase free medium. After the experiment, aortas were fixed with 1X 
Zamboni for 24 h and washed with 1X PBS until the colour of Zamboni is cleared, 
followed by over night washing.  The aortas were thereafter incubated in 18% (wt/vol) 
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saccharose over night, embedded in Tissue Tec and were frozen in liquid nitrogen. 6 
µm tissue sections were obtained at -20 °C on a Leica CM 3050S crystat and 
mounted with buffered glycerol onto frost free glass slides. 
 
3.11 Statistical analysis 
 
Data are given as means ± S.D. of 3-5 experiments using independent cell 
preparations. The comparison of means between groups was performed by oneway 
analysis of variance (ANOVA) followed by a Student-Newman-Keuls post-hoc test. 
Changes in parameters within the same group were assessed by multiple ANOVA 
analysis. Probability (P) values of less than 0.05 were considered significant (P< 
0.05). 
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4. Results 
 
4.1 Effect of postconditioning on hypoxia/reoxygenation-induced apoptosis in 
endothelial cells 
 To test whether postconditioning protects endothelial cells from 
hypoxia/reoxygenation-induced apoptosis, HUVEC were first induced to apoptosis by 
subjecting them to severe hypoxia (Po2 < 1 mmHg) for 2 h followed by 24 h 
reoxygenation. Postconditioning was applied at the onset of reoxygenation and cell 
death was analysed by annexin V/ PI staining in FACS, 24 h after reoxygenation, in 
comparision to cells that were reoxygenated after hypoxia, without the application of 
postconditioning.  
Hypoxia/reoxygenation led to an increase in apoptosis from 8.1± 0.9% to 19.2± 
1.4% in cultured endothelial cells. Application of hypoxic postconditioning at the 
onset of reoxygenation reduced the percentage of annexin V positive cells (Fig. 4.1) 
to basal values. Correspondingly, the loss in percentage of vital cell population due to 
hypoxia/reoxygenation was revived by postconditioning (Fig. 4.1). No significant 
changes were observed in percentage of necrotic cells.  
 
 
Fig. 4.1 Effect of hypoxia/reoxygenation and postconditioning on percentage of 
apoptotic cells: HUVEC were subjected to 2 h of severe hypoxia followed by 24 h of 
reoxygenation without (HR) and with (PC) postconditioning. Non-treated cells were 
taken as control (C). Distribution of vital, apoptotic and necrotic cells determined by 
FACS analysis. Data are means ± SD of 3 separate experiments with independent 
cell preparations. P < 0.05 vs C; P < 0.05;  n.s: not significantly different. 
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4.2 Effect of postconditioning on hypoxia/reoxygenation-induced cleavage of 
caspase-3 
  Cleavage of caspase-3, a central effector caspase of the apoptotic cascade, 
was measured to analyze the effect of postconditioning on hypoxia/reoxygenation-
induced apoptosis in endothelial cells. For this, HUVEC were induced to apoptosis by 
subjecting them to 2 h severe hypoxia, followed by 24 h reoxygenation. 
Postconditioning was applied at the onset of reoxygenation and caspase-3 cleavage 
was measured at 6 and 24 h after reoxygenation in comparision to cells that were 
reoxygenated after hypoxia without the application of postconditioning.  
As shown in fig. 4.2, severe hypoxia followed by 6 h reoxygenation caused a 
distinct 2.1± 0.3 fold increase in cleavage of caspase-3. This hypoxia/reoxygenation-
induced caspase-3 cleavage was abolished by the application of hypoxic 
postconditioning. The changes in cleavage of caspase-3 in response to 
hypoxia/reoxygenation and postconditioning were less distinct when measured after 
24 h of reoxygenation.  
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Fig. 4.2 Effect of hypoxia/reoxygenation and postconditioning on caspase-3 
cleavage: HUVEC were subjected to 2 h of severe hypoxia followed by 6 h and 24 h 
of reoxygenation without (HR) and with (PC) postconditioning. Non-treated cells were 
taken as control (C). (A) Representative Western blot showing cleavage of caspase-
3. Actin was taken as loading control. (B) Densitometric analysis of caspase-3 
cleavage at 6 h reoxygenation. Cleaved caspase-3 relative to actin is given as x-fold 
of control. The ratio of control was set to 1. Data are means ± SD of 3 separate 
experiments with independent cell preparations. P < 0.05 vs. C; P < 0.05. 
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4.3 Effect of postconditioning on inhibitor of apoptosis proteins, cIAP1, cIAP2 
and XIAP 
        Inhibitors of apoptosis proteins, known to be potential caspase-3 inhibiting 
proteins, were screened in this study for their expression in postconditioning. For this, 
HUVEC were subjected to postconditioning, following 2 h of severe hypoxia. Cells 
were harvested for protein lysates, at the end of postconditioning or at the end of the 
corresponding time period (30 min reoxygenation) for cells that were reoxygenated 
without postconditioning.     
       Western blot analysis showed that, cIAP2 but not its close homologues, cIAP1 or 
XIAP, is upregulated by severe hypoxia and declines to basal levels with 
reoxygenation. As shown in fig. 4.3, a striking increase of 6.4 ± 0.3 fold in the protein 
level of cIAP2 was observed with 2 h of severe hypoxia compared to normoxia. The 
protein level reduced to basal values in cells that were reoxygenated for 30 minutes. 
On the other hand, cells that were subjected to postconditioning showed a 7.6 ± 0.7 
fold increase in cIAP2 levels compared to normal hypoxia/reoxygenated cells that 
were taken as control. In contrast, the levels of cIAP1 and XIAP remained unchanged 
under corresponding conditions (Fig. 4.3).  
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Fig. 4.3 Effect of hypoxia/reoxygenation and postconditioning on protein levels of 
cIAP1, cIAP2 and XIAP: (A) Representative Western blots showing cIAP2, cIAP1 and 
XIAP under 2 h severe hypoxia (H) followed by 30 min reoxygenation without (HR) 
and with postconditioning (PC). Actin or vinculin (Vinc) was used for loading control. 
(B) Densitometric analysis of cIAP2 expression. cIAP2 relative to vinculin is given as 
x-fold of control. The ratio of control was set to 1. Data are means ± SD of 4 separate 
experiments with independent cell preparations. *P < 0.05 vs. C; #P < 0.05 vs HR. 
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4.4 Effect of cIAP2 silencing on hypoxia/reoxygenation-induced apoptosis and 
postconditioning        
       To confirm the role of cIAP2 in endothelial postconditioning, the protein was 
downregulated by transfecting with specific siRNA 24 h prior to the experiment. The 
efficiency of downregulation was checked by Western blot analysis by measuring 
cIAP2 protein content in transfected cells. Cells transfected with non-specific siRNA 
were taken as control, to nullify the effects of transfection procedure. A reduction of 
80 ± 12% in the protein levels of cIAP2 was achieved with cIAP2 siRNA in 
comparison to non-specific siRNA transfected cells (Fig. 4.4 A, B).  
      The effect of postconditioning on hypoxia/reoxygenation-induced apoptosis was 
measured in these cIAP2 downregulated cells. For this, HUVEC were transfected 
with non-specific or cIAP2 siRNA, 24 h prior to the application of 
hypoxia/reoxygenation or postconditioning. Cell death was analysed by annexin V/ PI 
staining in FACS, 24 h after reoxygenation. As shown in fig. 4.4 C, cIAP2 
downregulation caused a 1.7 ± 0.4 fold increase in the basal level of apoptosis in 
non-treated cells. As expected, hypoxia/reoxygenation lead to a significant increase 
in percentage of apoptosis compared to normoxic controls, in cells transfected with 
non-specific siRNA and cIAP2 siRNA as well. As observed previously in non-
transfected cells (Fig. 4.1), postconditioning abolished hypoxia/reoxygenation-
induced apoptosis in cells transfected with non-specific siRNA. However, this 
reduction of apoptosis by postconditioning was significantly less effective in cIAP2 
downregulated cells, confirming the protein‘s role in postconditioning. 
Correspondingly, postconditioning could revive the loss in percentage of healthy cells 
due to hypoxia/reoxygenation (HR), in non-specific siRNA transfected cells, while the 
revival effect was lost in cIAP2 downregulated cells (Fig. 4.4 C). 
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Fig. 4.4 Effect of cIAP2 downregulation on hypoxia/reoxygenation-induced apoptosis 
and postconditioning. HUVEC were transfected with cIAP2 siRNA 24 h prior to the 
application of hypoxia/reoxygenation (HR) or postconditioning (PC). Non-treated cells 
were taken as control (C). (A) Representative Western blot showing downregulation 
of cIAP2 with cIAP2 specific siRNA (cIAP2 si) in comparison to non-specific control 
siRNA (NS si). Non-transfected cells were taken as control (NT). Vinculin was taken 
as internal loading control. (B) Densitometric analysis of cIAP2 relative to Vinculin, 
given as percentage of control. Data are means ± SD of 5 separate experiments with 
independent cell preparations. 
*
P < 0.05 vs. NS si; n.s: not significantly different. (C) 
Distribution of vital, apoptotic and necrotic cells determined by FACS analysis of cells 
treated with cIAP2 siRNA compared to those treated with non-specific siRNA (NS si). 
Data are means ± SD of 3 separate experiments with independent cell preparations. 
*
P < 0.05 vs. C;
 #
P < 0.05; n.s: not significantly different. 
C 
C 
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4.5 Effect of cIAP2 silencing on hypoxia/reoxygenation-induced caspase-3 
cleavage and postconditioning 
       In addition to FACS analysis, the effect of postconditioning on hypoxia/ 
reoxygenation-induced caspase-3 cleavage was measured in cIAP2 downregulated 
cells, to confirm the role of cIAP2 in endothelial postconditioning.   
       Following 24 h of transfection with non-specific siRNA or cIAP2 specific siRNA, 
HUVEC were subjected to severe hypoxia. Caspase-3 cleavage was measured 6 h 
after reoxygenation or postconditioning. Consistent with the previous observation 
(Fig. 4.2), hypoxia/reoxygenation caused an increase in cleavage of caspase-3 which 
was effectively abolished by postconditioning (Fig 4.5). Treatment with non-specific 
siRNA showed no influence on the protective effect of postconditioning in reducing 
hypoxia/reoxygenation-induced caspase-3 cleavage. However, postconditioning 
failed to abolish hypoxia/reoxygenation-induced caspase-3 cleavage in cells treated 
with cIAP2 siRNA (Fig. 4.5) 
 
 
Fig. 4.5 Effect of cIAP2 silencing on caspase-3 cleavage under 
hypoxia/reoxygenation and postconditioning. Cells were transfected with cIAP2 
siRNA or non-specific siRNA (NS si), 24 h prior to the application of 
hypoxia/reoxygenation (HR) or postconditioning (PC). Non-treated cells were taken 
as control (C). Representative Western blot showing cleavage of caspase-3. Actin 
was taken for internal loading control. 
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4.6 Effect of hypoxia/reoxygenation and postconditioning on cIAP2 - 
procaspase-3 interaction 
       cIAPs are known to execute their anti-apoptotic function by directly binding to 
specific procaspases and inhibiting their proteolytic activation (Roy et al., 1997). To 
test whether cIAP2 directly binds to procaspase-3 in endothelial cells under 
hypoxia/reoxygenation and postconditioning, co-immunoprecipitation of both the 
proteins and their co-localization were studied. HUVEC were subjected to 2 h of 
severe hypoxia followed by reoxygenation or postconditioning. 
Anti-procaspase-3 antibody coated beads were used to coimmunoprecipitate 
procaspase-3 with its interacting partners from protein lysates of cells subjected to 
hypoxia/reoxygenation or postconditioning. As shown in fig 4.6 A, cIAP2 was co-
immunoprecipitated with the caspase-3 zymogen under conditions of hypoxia and 
postconditioning, while no binding was observed under control or reoxygenation 
conditions. 
        In accordance with the coimmunoprecipitation studies, co-staining of cIAP2 and 
procaspase-3 in immunocytochemistry showed increased co-localization of both 
proteins in the peri-nuclear regions, during hypoxia and postconditioning compared to 
control or reoxygenated cells (Fig. 4.6B).  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
A 
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Fig. 4.6 Effect of hypoxia/reoxygenation and postconditioning on cIAP2 - 
procaspase-3 interaction. HUVEC were subjected to 2 h hypoxia (H) followed by 
reoxygenation without (HR) and with postconditioning (PC). Non-treated cells were 
taken as control (C). (A) Representative Western blot showing co-
immunoprecipitation of cIAP2 with procaspase-3 under hypoxia and postconditioning, 
while no binding was observed under control and reoxygenation conditions (B) 
Immunostaining of procaspase-3 (green) and cIAP2 (red), showing increased co-
locolization of both the proteins (yellow), under hypoxia and postconditioning 
compared to reoxygenation and control conditions.  
B 
A 
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4.7 Effect of postconditioning on PI3-kinase and MAPKs in endothelial cells 
       Mitogen activated protein kinases and the PI3-Kinase pathway play a major role 
in various anti-apoptotic/pro-survival mechanisms. The activation of Akt, ERK1/2, p38 
MAPK and JNK pathways in endothelial postconditioning was examined as an initial 
step to identify the mechanism by which cIAP2 is maintained in postconditioning. 
      For this, HUVEC were subjected to postconditioning, following 2 h of severe 
hypoxia. Cells were harvested for protein lysates at the end of postconditioning or at 
the end of the corresponding time period (30 min reoxygenation) in cells that were 
reoxygenated without postconditioning. Phosphorylation of the kinases was detected 
in Western blotting as a measure of their activation. As shown in fig 4.7, a significant 
increase in the phosphorylation of Akt, ERK1/2 and p38 MAPK was observed during 
postconditioning in comparison to cells that were normally reoxygenated after 
hypoxia. Phosphorylation of c-jun remained unchanged under all corresponding 
conditions, negating the role of the stress activated protein kinase in endothelial 
postconditioning. 
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Fig. 4.7 Effect of postconditioning on phosphorylation of PI3 kinase and MAPKs. 
HUVEC were subjected to 2 h severe hypoxia (H) followed by 30 min reoxygenation, 
without (HR) or with postconditioning (PC). Representative Western blots showing 
phosphorylation of Akt, ERK1/2, p38MAPK and c-Jun. Duplicate samples were taken 
for each condition. Actin or vinculin was taken for internal loading control.  
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4.8 Role of PI3 kinase and MAPKs in the maintenance of cIAP2 by 
postconditioning  
       Pharmacological inhibition of the kinases that were found to be activated during 
postconditioning in endothelial cells was used as a strategy to test the involvement of 
those kinases in the maintenance of cIAP2 by postconditioning. Accordingly, HUVEC 
were subjected to postconditioning in the presence of the Akt inhibitor LY294002, 
MEK-1/2 inhibitors PD98059 or UO126, the p38 MAPK inhibitor SB203580 or the c-
jun inhibitor SP600125. DMSO treated cells were taken as vehicle control.  
       As observed previously (Fig. 4.3), postconditioning prevented the loss of cIAP2 
during reoxygenation (Fig. 4.8). However, inhibitors of both Akt and ERK 1/2 
phosphorylation attenuated the high levels of cIAP2 in postconditioning, indicating 
their role as upstream targets of cIAP2 (Fig. 4.8). Despite the increase in p38 MAPK 
phosphorylation during postconditioning (Fig. 4.7), its inhibition had no significant 
effect on the maintenance of cIAP2 in postconditioning (Fig. 4.8), suggesting a non-
causal role of the kinase activation in cIAP2 mediated protection in postconditioning.  
Inhibition of c-jun phosphorylation had no effect on cIAP2 in postconditioning (Fig. 
4.8). Treatment with DMSO has no effect on the maintenance of cIAP2 by 
postconditioning. 
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Fig. 4.8 Effect of PI3 kinase and MAPK inhibitors on cIAP2 under postconditioning. 
HUVEC were subjected to postconditioning in the presence of PD98059 (20 µM), 
UO126 (10 µM), SB203580 (10 µM), SP600125 (10 µM), LY294002 (10 µM) or 
DMSO (10 µM). Cells subjected to postconditioning in the presence DMSO were 
taken as vehicle control. (A) Representative Western blot showing cIAP2 in non-
treated control (C), hypoxia (H), hypoxia/reoxygenation (HR) and during 
postconditioning in the absence (NT) and presence of specific kinase inhibitors. 
Vinculin (Vinc) was taken for internal loading control. (B) Densitometric analysis of 
cIAP2 relative to Vinculin, given as percentage of control. The ratio of control was set 
to 100. Data are means ± SD of 3 separate experiments with independent cell 
preparations. 
*
P < 0.05 vs. HR;
 #
P < 0.05 vs. vehicle n.s: not significantly different vs. 
vehicle. 
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4.9 Effect of hypoxia/reoxygenation and postconditioning on cIAP2 expression 
in the rat aorta 
      To confirm the relevance of cIAP2 expression in reponse to hypoxia, 
reoxygenation and postconditioning, in endothelial monolayers, an intact vessel 
model was established using rat aortas. Freshly excised rat aortas were subjected to 
2 h of hypoxia, followed by reoxygenation or postconditioning, using the same 
protocol applied for cultured endothelial cells. Immunofluorescence labeling of the 
sectioned aortas showed an increase in staining of cIAP2 in the endothelium 
(identified by von Willebrand factor) with 2 h hypoxia. In accordance with the effect 
observed in cultured endothelial cells, reoxygenation caused a decrease in cIAP2, 
while postconditioning prevented the loss of cIAP2 with reoxygenation in the intact 
vessel as well (Fig. 4.9).  
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Fig. 4.9 Effect of hypoxia/reoxygenation and postconditioning on immunostaining of 
cIAP2 in the rat aorta. (Upper panel) Immunostaining of rat aorta cryosections 
showing differences in cIAP2 staining (red) in the endothelium of vessels subjected to 
hypoxia (H), hypoxia/reoxygenation (HR) or postconditioning (PC). Non-treated 
aortas were taken as control (C). DAPI (blue) was used as a nuclear stain. (Lower 
panel left) Immunostaining of von Willebrand factor (red) indicates endothelium. 
(Lower panel right) Non-stained section of the aorta was taken for negative control 
(neg. control).  
neg. 
control 
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5. Discussion 
 
       In the present study, the effect of postconditioning on endothelial cell survival 
and the molecular mechanisms involved were investigated. Postconditioning has 
emerged as a clinically feasible intervention, well-proven to effectively reduce 
reperfusion injury in cardiomyocytes (Zhao et al., 2003). However, little is known 
about the effects of this maneuver in endothelial cells and whether it has an influence 
on apoptosis, which is the predominant form of endothelial cell death in the 
reperfused myocardium. In an attempt to study this, endothelial cells were exposed to 
hypoxia/reoxygenation and the effects of postconditioning on cell survival as well as 
the underlying molecular mediators were examined. 
       The major findings of the present study are: (a) Postconditioning protects 
cultured endothelial cells from hypoxia/reoxygenation-induced apoptosis. (b) Cellular 
inhibitor of apoptosis protein 2, cIAP2, but not cIAP1 or XIAP is upregulated during 
hypoxia and its loss during reoxygenation is prevented by postconditioning. This 
effect of postconditioning on cIAP2 stabilization was observed in cultured endothelial 
cells as well as in intact vessels. (c) Downregulation of cIAP2 with siRNA augments 
hypoxia/reoxygenation-induced apoptosis and diminishes the protective effect of 
postconditioning. (d) cIAP2 directly interacts with pro-caspase3 in hypoxia and 
postconditioning. (e) ERK1/2 and PI3 Kinase pathways, but not p38 MAPK or the 
JNK pathway, are involved in the maintenance of cIAP2 in endothelial 
postconditioning. 
  
5.1 Postconditioning protects endothelial cells from hypoxia/reoxygenation-
induced apoptosis 
        This study shows for the first time that postconditioning, known to rescue 
cardiomyocytes from reperfusion injury, also has an effect on endothelial cells. 
According to the principle that the first few minutes of reperfusion provide the ‗window 
of opportunity‘ (Piper et al., 2004), intermittent hypoxia applied at the very onset of 
reoxygenation reduced the caspase-3 cleavage and apoptosis induced by 
hypoxia/reoxygenation. Correspondingly, postconditioning could revive the loss in 
percentage of healthy cells induced by hypoxia/reoxygenation, while there were no 
significant changes in the percentage of necrotic cells. 
       The increase in percentage of apoptosis in response to hypoxia/reoxygenation 
can be explained by the robust energy metabolism of endothelial cells, which allows 
 63 
them to maintain high phosphorylation potential, even in adverse conditions like 
ischemia or hypoxia. This ability to maintain their ATP levels prevents endothelial 
cells from the necrotic fate (Lelli et al., 1998), resulting in no significant changes in 
percentage of necrosis, in response to hypoxia/ reoxygenation or postconditioning.  
      Increasing evidence suggests that loss of endothelial integrity leads to leakage 
of cytokines, interleukins and other pro-inflammatory mediators, jeopardizing the 
survival of the entire myocardial tissue (Bombeli et al., 1997, Werner et al., 2006). 
Hence it is likely that prevention of apoptosis, which is the predominant form of cell 
death in the endothelium, comprises a significant fraction of the protection exerted by 
postconditioning. This is further supported by studies reporting endothelial apoptosis 
as a critical event preceding myocardial apoptosis during ischemia reperfusion injury 
(Scarabelli et al., 2001). It was also reported that during ischemia, inhibition of 
caspase-9, the principal initiator caspase of the endothelium, and not inhibition of 
caspase-8, which is found in the cardiomyocytes, leads to a reduction in infarct size 
(Stephanou et al., 2001), suggesting that prevention of endothelial apoptosis, could 
be critical in determining the outcome of reperfusion injury in the myocardium. The 
systematic nature of this cell death process, unlike necrosis, allows greater chances 
for therapeutic interventions and revival. 
The algorithm of postconditioning applied in this study effectively abolished 
reoxygenation-induced caspase-3 cleavage and apoptosis, reviving the loss in 
percentage of vital cell population. Though postconditioning was originally performed 
on the canine heart, by the application of 3 cycles of ischemia and reperfusion, each 
lasting for 30 sec (Zhao et al., 2003), the optimal algorithm for postconditioning can 
vary widely depending on the species and the experimental model under study 
(Skyschally et al., 2009). 3 cycles of severe hypoxia and reoxygenation, 5 min each, 
were applied in this study, which is established to be optimal for cell culture models 
(Sun et al., 2005). 
 
5.2 Inhibitors of apoptosis proteins in postconditioning 
     The Inhibitors of apoptosis family of proteins are known to play pivotal roles in a 
wide variety of pro-survival and anti-apoptotic pathways by inhibiting caspases, the 
key mediators of apoptosis. Here, the involvement of IAPs in the protective effect of 
postconditioning on endothelial cells was examined. Among the IAPs screened in the 
study, only cIAP2 was found to be upregulated by hypoxia. Importantly, 
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reoxygenation leads to a loss in cIAP2, which is prevented by the application of 
postconditioning. The protein levels of cIAP1 and XIAP remained unchanged in 
response to hypoxia/reoxygenation or postconditioning. 
       Focus was laid on the IAP family of proteins among all other known hypoxia-
sensitive anti-apoptotic molecules, because of the converging downstream 
positioning of IAPs in both the intrinsic and extrinsic apoptotic pathways. IAPs act to 
directly suppress the activity of caspases, which are the key apoptotic executors. 
Further, the loss of cIAP2 at reoxygenation supports the hypothesis that a maneuver 
to prevent the loss could protect the cells from apoptosis. This makes cIAP2 an 
interesting candidate for postconditioning. Bcl2, for instance is one of the other 
hypoxia sensitive anti-apoptotic proteins, but the continued endogenous expression 
of this protein in reoxygenation has no protective effect, still allowing apoptosis to 
occur in reperfusion injury (Mishra et al., 2006). Similar is the case with Bcl-xL, 
making these proteins less plausible candidates to be involved in postconditioning. 
cIAP2, on the other hand, is upregulated as an adaptive response to hypoxia but 
reduces to basal levels with the onset of reoxygenation. As demonstrated by the 
present study, postconditioning indeed strengthens this adaptive response induced 
by hypoxia and prevents the loss of cIAP2 with the onset of reoxygenation. 
Although other mammalian IAPs and particularly cIAP1, share a highly conserved 
structural and functional homology with cIAP2 including an NFкB response element, 
it is not yet clear what distinguishes cIAP2 from the others in terms of its hypoxia 
sensitivity. A previous study by Dong et al., (2001) supports our observation that only 
cIAP2, but not cIAP1 is upregulated by hypoxia. The upregulation was reported to be 
HIF-independent, but the specific mechanism remains to be elucidated.  
 
5.3 Effect of cIAP2 silencing on hypoxia/reoxygenation-induced apoptosis and 
postconditioning 
       The functional significance of cIAP2 expression in endothelial postconditioning 
was tested by silencing the protein with specific siRNA before the application of 
hypoxia/reoxygenation or postconditioning. About 80% downregulation in the protein 
levels of cIAP2 was achieved in comparison to non-specific siRNA treated cells taken 
as control. As expected, cIAP2 silencing slightly increased the basal level of 
apoptosis in normal growing cells. Hypoxia/reoxygenation led to an increase in 
cleavage of caspase-3 and percentage of apoptosis, in both cIAP2 siRNA and non-
 65 
specific siRNA treated cells. This was accompanied by a corresponding loss in 
percentage of vital cell population, in both cases. As observed in non-treated cells, 
postconditioning effectively abolished hypoxia/reoxygenation-induced apoptosis in 
cells transfected with non-specific siRNA. However, the protective effect of 
postconditioning was diminished in cIAP2 downregulated cells, as seen by the failure 
of the maneuver to reduce hypoxia/reoxygenation-induced caspase-3 cleavage and 
apoptosis in these cells. Correspondingly, postconditioning was effective in reviving 
hypoxia/reoxygenation-induced loss in percentage of vital cell population in non- 
specific siRNA treated cells, but not in cIAP2 downregulated cells. 
       cIAP2 appears to be one of the anti-apoptotic molecules central in balancing the 
apoptotic machinery of endothelial cells. This is evident from the fact that, cIAP2 
silencing even causes an increase in the basal level of apoptosis in normal growing 
cells that are unexposed to hypoxia/reoxygenation. The drastically high levels of the 
protein in postconditioning and the significant antagonizing effect of its silencing on 
the protective effect of postconditioning strongly emphasize the crucial role of cIAP2 
in endothelial postconditioning.  
 
5.4 Interaction of cIAP2 and procaspase-3 
      Based on the previously reported observation that cIAP1 and cIAP2 inhibit 
apoptosis by directly binding to procaspase-3 (Roy et al., 1997), it was hypothesized 
that the elevated levels of cIAP2 in postconditioning might prevent reoxygenation 
induced apoptotic execution by directly binding to procaspase-3 and preventing its 
cleavage to active subunits. The hypothesis was tested by studying the interaction of 
both the proteins in endothelial cells subjected to hypoxia/reoxygenation or 
postconditioning. Co-immunoprecipitation of cIAP2 with procaspase-3 showed direct 
interaction of the two proteins under conditions of hypoxia and postconditioning. This 
was further supported by immunocytochemical images showing increased co-
localization of both the proteins in the peri-nuclear regions of the cell, under hypoxia 
and postconditioning.  
          In several cases, the BIR domain of IAPs enables them to bind caspases and 
suppress their activity (Devereaux et al., 1997). However cIAP1 and cIAP2 also 
possess an exclusive caspase recruitment domain (CARD), the function of which is 
not yet completely understood. It is not yet known whether the BIR or the CARD 
domain of cIAP2 binds to procapase-3 in endothelial cells, but it may be speculated 
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that either of the two domains or both of them could be potential motifs responsible 
for the protein‘s binding to procaspase-3 thereby leading to its inactivation during 
postconditioning in endothelial cells. 
 
5.5 Role of PI3-kinase and MAPKs in the maintenance of cIAP2 by 
postconditioning  
        As an initial step to identify the signaling mechanism involved in the 
maintenance of cIAP2 by postconditioning, the activation of Akt and MAPK pathways 
in endothelial postconditioning was examined. The expression of cIAP2 in 
postconditioning was then studied by performing postconditioning in the presence of 
pharmacological inhibitors of those kinases that are found to be activated during 
postconditioning.  
        Increase in phosphorylation of Akt, ERK1/2 and p38 MAPK was observed in 
postconditioning compared to hypoxia/reoxygenation in endothelial cells. There were 
no significant changes in the phosphorylation state of c-jun. In accordance to this, 
pharmacological inhibition of PI3-kinase and ERK1/2 prevented the maintenance of 
cIAP2 by postconditioning. On the contrary, inhibition of p38 MAPK had no effect on 
the protein levels of cIAP2 during postconditioning, in spite of the fact that 
phosphorylation of p38 MAPK was observed in endothelial postconditioning, 
excluding p38 MAPK as an upstream signaling element in cIAP2 maintenance. The 
levels of phospho c-jun remained unchanged, suggesting that the stress-activated 
JNK pathway is not involved in endothelial postconditioning. 
       Activation of PI3-kinase and ERK1/2 pathways during postconditioning in 
endothelial cells is similar to cardiomyocytes (Hausenloy et al., 2004), where both the 
pathways were found to be activated during postconditioning. ERK1/2 and PI3-kinase 
are collectively called as reperfusion injury salvage kinases (RISK) and their 
activation is reported to protect against reperfusion injury (Hausenloy et al., 2004).  
The mechanism by which these survival kinases are recruited by postconditioning is 
still unresolved, although it is suggested that it may be due to activation of cell-
surface receptors including the adenosine A2A receptor (Morrison et al., 2007). Other 
studies have placed its activation downstream of other signaling elements such as 
sphingosine kinase (Jin et al., 2008) and the recovery of neutral pH in the first few 
minutes of myocardial reperfusion (Fujita et al., 2007). The downstream targets of 
RISK are better resolved and converge on inhibition of mPTP opening, principally via 
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GSK-3ß (Halestrap et al., 1998; Gomez et al., 2008). Further, the mechanism by 
which activation of PI3-kinase and ERK1/2 lead to stabilization of cIAP2 in 
endothelial postconditioning is yet to be determined. However, pharmacological 
inhibition clearly indicates their upstream role in the maintenance of cIAP2 during 
postconditioning.  
In addition, p38 MAPK was also found to be activated in endothelial postconditioning. 
The role of p38 MAPK in cardiac conditioning has frequently countered controversy, 
with studies reporting both cardio-protective (da Silva et al., 2004) and pro-injurious 
(Sun et al., 2006) roles of the kinase at the time of reperfusion (Ping et al., 2000; 
Hausenloy et al., 2007). In our model, p38 MAPK was observed to be activated 
during postconditioning, however, blocking the kinase by pharmacological inhibition 
had no effect on cIAP2, indicating that the activation plays no role in the maintenance 
of cIAP2 during postconditioning. 
 
5.6 cIAP2 expression in the intact vessel 
       To test the expression of cIAP2 during hypoxia/reoxygenation and 
postconditioning in the intact vessel, a vessel model using rat aorta was established. 
The endothelium in the intact vessel showed an increased expression of cIAP2 in 
response to hypoxia. Reoxygenation led to a loss in signal intensity, which was 
prevented in the postconditioned vessel.  
      The expression pattern of cIAP2 in response to hypoxia/reoxygenation and 
postconditioning was very similar to the cell culture model, negating the occurrence 
of any cell culture artifacts. The increased expression of cIAP2 under 
postconditioning, seen in the intact vessel model, confirms the functional significance 
of the anti-apoptotic protein in endothelial postconditioning. It was also observed that 
the endothelium, identified by von Willebrand factor, showed more cIAP2 than the 
surrounding tissue, suggesting the importance of endothelial postconditioning. 
 
5.7 Future perspective 
      Postconditioning is gradually being adapted into clinical practice in cases of 
coronary intervention, cardiac surgery, organ transplantation and vascular-based 
procedures. However, it has not yet assumed the position of ‗standard care‘ in any of 
the clinical settings. Further insight into the molecular mechanisms of 
postconditioning, the signaling pathways recruited and the cell types involved is 
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necessary to establish postconditioning as a standard clinical practice to counteract 
reperfusion injury. In this context, understanding endothelial cell responses is 
essential since they are in direct contact with the blood carrying triggers and 
mediators of hypoxia/reperfusion and postconditioning, including oxidants, cytokines, 
interleukins, chemokines and ionic dyshomeostasis. The present study shows that 
endothelial cells do respond to postconditioning and that cIAP2 is crucial for the anti-
apoptotic effect exerted. It was also observed that ERK1/2 and PI3-kinase are 
involved in the maintenance of cIAP2 by postconditioning, however, the mechanism 
by which postconditioning leads to activation of the kinases and how this activation 
controls cIAP2 content in the cells, remain to be elucidated.  
       Prevention of the mPTP opening, which is a crucial step in postconditioning of 
cardiomyocytes, would also be a question of interest in endothelial postconditioning. 
Phosphorylation of GSK-3ß, which leads to its inactivation, is known to prevent the 
opening of mPTP, and thus exert cardioprotection (Gomez et al., 2008). Whether 
such inactivation of GSK-3ß occurs in endothelial postconditioning or not, is yet to be 
determined.  
       Finally, in vivo experiments designed to study the role of endothelial 
postconditioning on the outcome of myocardial protection, would help to further 
validate the patho-physiological relevance of the current study and to better adapt 
postconditioning into clinical practice. 
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7. Summary 
          
       Postconditioning (intermittent hypoxia at the onset of reperfusion), a strategy 
known to effectively reduce reperfusion injury, is well proven in cardiomyocytes. 
However, little is known about postconditioning in endothelial cells and whether it 
plays a role in anti-apoptosis, which is the predominant form of cell death in 
endothelial cells. Here the protective effect of postconditioning in endothelial cells 
and the molecular mechanisms involved were studied, focusing on the inhibitors of 
apoptosis proteins (IAPs) as potential anti-apoptotic candidates induced by hypoxia. 
Exposure of human umbilical vein endothelial cells to severe hypoxia (Po2 < 1 
mmHg) for 2 h caused a 2.1 ± 0.3 fold increase in caspase-3 cleavage, 6 h after 
reoxygenation and a 2.3 ± 0.2 fold increase in apoptosis (annexin V staining) 24 h 
after reoxygenation. Postconditioning abolished hypoxia/reoxygenation-induced 
apoptosis in endothelial cells. Quest for possible anti-apoptotic molecules led to the 
observation that cIAP2 but not its close homologue cIAP1 or XIAP, is upregulated 
during hypoxia and reduces to basal level with the onset of reoxygenation. 
Importantly, cIAP2 could be maintained by postconditioning in an ERK1/2 and PI3-
Kinase dependant manner. Hypoxia as well as postconditioning induced an 
interaction between cIAP2 and procaspase-3 (co-immunoprecipitation and co-
localization in immunochemistry), suggesting a mechanism by which cIAP2 
counteracts hypoxia/reoxygenation-induced apoptosis. Downregulation of cIAP2 with 
siRNA enhanced hypoxia/reoxygenation-induced apoptosis and abolished the 
protective effect of postconditioning. Maintenance of cIAP2 by postconditioning in the 
intact vessel confirms the patho-physiological significance of the finding. The present 
study shows for the first time that postconditioning can protect endothelial cells 
against hypoxia/reoxygenation-induced apoptosis. This protective effect is conferred 
by the cIAP2, which is expressed during hypoxia and could be maintained at an 
elevated level by postconditioning, interacting with procaspase-3. 
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8. Zusammenfassung 
 
Postkonditionierung (Phasen intermittierender Hypoxie zu Beginn einer 
Reperfusion) ist eine wirksame Strategie, die das Ausmaß des kardiomyozytären 
Reperfusionsschadens reduzieren kann. Es ist jedoch unklar, welche Wirkung die 
Postkonditionierung auf die endotheliale Apoptose hat, welche die vorherrschende 
Form des Zelluntergangs darstellt. Ziel dieser Arbeit war es daher, die protektive 
Wirkung der Postkonditionierung und die zu Grunde liegenden molekularen 
Mechanismen in Endothelzellen zu untersuchen. Der Fokus lag dabei auf einer 
Familie Apoptose-inhibierender Proteine (Inhibitors of Apoptosis Proteins, IAPs) als 
potentielle anti-apoptotische Kandidaten, die durch Hypoxie induziert werden. 
Humane Endothelzellen aus Nabelschnurvenen, die einer zweistündigen Hypoxie 
(Po2 < 1 mmHg) ausgesetzt wurden, zeigten nach sechstündiger Reoxygenierung 
einen 2,1 ± 0,3-fachen Anstieg der Caspase 3-Aktivität (Westernblot) und nach 24 
Stunden Reoxygenierung eine 2,3 ± 0,2-fache Steigerung der Apoptoserate (Annexin 
V-Färbung). Postkonditionierung im Anschluss an die zweistündige Hypoxie 
reduzierte die Hypoxie/Reoxygenation (H/R)-induzierte Apoptose. Die Suche nach 
möglichen antiapoptotischen Molekülen ergab, dass der zelluläre Gehalt an cIAP2, 
nicht jedoch der von cIAP1 oder XIAP, während Hypoxie anstieg. Mit Einsetzen der 
Reoxygenation sank der cIAP2-Gehalt wieder auf das Ausgangsniveau. Durch 
Postkonditionierung konnte ERK1/2- und PI3-Kinase-abhängig der cIAP2-Gehalt auf 
dem post-hypoxischen Niveau gehalten werden. Hypoxie sowie Postkonditionierunng 
induzieren die Interaktion zwischen cIAP2 und Pro-Caspase 3 (Co-
Immunoprezipitation bzw. Co-Lokalisation im immunzytologischen Nachweis). Die 
gezielte Herunterregulation von cIAP2 durch Einsatz von siRNA führte zu einer 
Verstärkung der H/R-induzierten Apoptose und hob die protektive Wirkung der 
Postkonditionierung. Die Aufrechterhaltung von cIAP konnte in Untersuchungen an 
intakten Gefäßen bestätigt werden. Die vorliegende Arbeit erstmalig, dass 
Postkonditionierung Endothelzellen vor einer H/R-induzierten Apoptose schützt. 
Dieser Effekt wird durch cIAP2 vermittelt, das während Hypoxie verstärkt exprimiert 
wird und dessen Konzentration durch Postkonditionierung auf dem posthypoxischen 
Niveau gehalten werden kann und mit Procaspase-3 interagiert. 
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